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ABSTRACT
This dissertation aimed at filling gaps in the body of Parkinson’s disease (PD) and sleep
literature by synthesizing and appraising current knowledge on the influence of sleep on healthrelated quality of life (HRQoL) in persons with Parkinson’s (PWP) and their caregivers,
conducting a psychometric evaluation of a HRQoL instrument among PWP, and applying a
novel method to assess the dyadic relationship between sleep and HRQoL in PWP and their
caregivers.
First, the systematic literature review results showed that nocturnal and diurnal sleep
problems among PWP are strong predictors of their HRQoL. Additionally, studies that focused
on caregiver outcomes showed that PWP and caregivers’ sleep issues were predictors of
caregiver HRQoL. Results synthesized across these studies suggest that the relationship between
sleep and HRQoL might be interdependent for PWP and caregivers.
Second, a cross-sectional study was conducted to evaluate the Patient-Reported
Outcomes Measurement Information System (PROMIS) Global Health, a generic HRQoL
instrument, among PWP. Findings from this study provide evidence that the global physical
health (GPH) and global mental health (GMH) summary scores obtained from this instrument
show good reliability and validity in PWP.
Finally, a cross-sectional study was conducted to assess the dyadic relationship between
sleep and HRQoL among PWP and caregivers using the Actor-Partner Interdependence Model.
This study used the PROMIS sleep disturbance (SD) and the PROMIS sleep-related impairment
ii

(SRI) to measure nocturnal and diurnal sleep issues, respectively. Results showed that both SD
and SRI in PWP and their caregivers are significant predictors of their own HRQoL.
Additionally, caregiver’s SD and SRI were found to be significant predictors of PWP’s HRQoL.
These results provide empirical evidence that the sleep-HRQoL relationship is not an
independently occurring phenomenon for PWP and caregivers.
Study findings about the impact of sleep on HRQoL among PWP and their caregivers
help provide a better understanding of this complex relationship in PD. Interventions aiming to
improve PWP’s HRQoL might benefit from integrating services that also address caregivers’
sleep. Such interventions have the potential to reduce humanistic burden in this population and
economic burden on the society by way of decreasing institutionalization rates among PWP.
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CHAPTER 1: INTRODUCTION
Overview of Parkinson’s disease
Parkinson’s disease (PD) is a progressive neurodegenerative disease condition caused by
loss of dopaminergic neurons in the midbrain. This results in some of the most commonly
associated symptoms with the disease such as tremors at rest, akinesia (paucity of movement),
bradykinesia (slowness in movement), muscle rigidity, gait and balance problems.1,2 PD was
thought of as a purely movement-related disorder with one or more of the above symptoms.
However, overwhelming evidence suggests that there are several non-motor symptoms (NMS)
that occur alongside these motor symptoms such as cognitive changes, fatigue, hallucinations
and delusions, mood disorders, orthostatic hypotension, pain, and sleep disorders among others.3
Presence of motor symptoms in patients usually triggers a diagnosis for PD, however, NMS are
present in a patient well before the manifestation of motor symptoms and carry on in to the final
palliative stages of the disease.4,5
Diagnosis and treatment
The Movement Disorder Society (MDS) criteria for a PD diagnosis requires presence of
parkinsonism (defined as having bradykinesia plus either tremor at rest or rigidity) accompanied
by additional diagnostic features to confirm a clinically established or a clinically probable PD
case, depending on the range of criteria satisfied.6 These diagnostic features are listed below:
•

Absolute exclusion criteria are comprised of other conditions that could explain the
existing parkinsonism thereby ruling out a PD diagnosis. These conditions include but are
1

•

not limited to presence of cerebellar abnormalities, primary progressive aphasia, cortical
sensory loss, presence of drug-induced parkinsonism due to use of dopamine receptor
blockers or dopamine-depleting agents.

•

Red flags delineate criteria which must be counterbalanced by supportive criteria to allow
for PD diagnosis and point to unusual patterns of disease progression following disease
onset. Examples include “rapid progression of gait impairment requiring regular use of
wheelchair within 5 years of onset”, “recurrent falls because of impaired balance within 3
years of onset” etc.

•

Supportive criteria define criteria that strengthen confidence in a PD diagnosis. These
include characteristics such as “clear and dramatic beneficial response to dopaminergic
therapy….”, “presence of levodopa-induced dyskinesia” etc.
Levodopa, as dopamine replacement therapy, has remained the drug of choice for treating

PD since the late 1960s when it was discovered.7 Additional treatment options consist of
dopamine agonists (DA), monoamine oxidase B (MAO-B) inhibitors, nonergot, ergot, catecholo-methyltransferase (COMT) inhibitors, synaptic vesicle glycoprotein 2A (Sv2a)
agonists/channel blockers, anticholinergics, amantadine, deep brain stimulation (DBS) and others
for treating motor symptoms.8 There are several therapies available to treat NMS, some of which
are specific to individual NMS in PD patients while others might not be tailored to address these
symptoms specifically in this patient population.9
Epidemiology
Following Alzheimer’s disease, PD is the second most common degenerative disease of
the central nervous system. The prevalence of the disease increases with age, with estimates
ranging from 41 per 100,000 in the 40-49 years age group to 1,087 per 100,000 for 70-79
2

years.10 The prevalence rate has also been reported to vary by sex and geographic location, both
worldwide and within North America.10,11 Kowal et al. reported a national prevalence of 630,000
individuals with PD in 2010 and a total economic burden of $14.4 billion in the US.12
Health-related quality of life of individuals with Parkinson’s Disease
PD is a progressive neuromuscular disease and therefore, the main clinical priority is to
restore or slow down loss of motor control. However, since this disease progresses slowly, and
most PD patients live in the community, optimizing health-related quality of life (HRQoL) is
also an important treatment goal. Patients’ HRQoL in PD is a complex construct influenced by
the following factors: motor symptoms, motor complications, deteriorating psychosocial
functioning, disease severity, and NMS such as sleep disorders, depression, cognition, pain,
fatigue, apathy, and speech impairment.13–16 Moreover, several studies have shown that NMS
have a greater significance for a patient’s HRQoL, healthcare resource utilization, caregiver
HRQoL and caregiving burden.17–20 Among all NMS, sleep disorders are the most frequently
reported symptom, with some studies estimating a prevalence rate over 90%,17,21,22 and severely
impact patient HRQoL.23–25
Role of caregivers in Parkinson’s Disease
PD is a neurological condition where patients’ symptoms, functioning and well-being
deteriorate progressively with time. As a result, patients experience physical limitations
including their ability to conduct activities of daily living, and cognitive and psychiatric
complications.20 PD patients may need a caregiver’s assistance with activities such as personal
safety, mobility, transportation, medication compliance, meal preparation, housework, chores,
shopping, finances, personal care and social involvements.20,26 Most caregivers of patients with
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PD are family members.20 Caregiving is a time-intensive activity and is an important predictor of
reduced rates of institutionalization among patients.27,28 However, caregivers of patients with PD
face significant economic burden, increased caregiver burden and reduced HRQoL, as a result of
caregiving.19,29–32
Sleep disorders in Parkinson’s disease
Sleep disorders have long been studied as a frequently reported NMS among PD patients.
Previous studies have estimated a 60%-90% prevalence of one or more sleep-related disorders
among PD patients.33,34 The most common sleep disorders seen among PD patients are rapid eye
movement (REM) sleep behavior disorder (RBD), insomnia, nocturia, restless legs syndrome
(RLS)/periodic limb movement disorder (PLMD), sleep disordered breathing (SDB), excessive
daytime sleepiness (EDS), and circadian rhythm disorders.33 There are several factors that
contribute to sleep disturbances in PD patients including pathological degeneration of sleep
regulation in the brainstem and thalamocortical pathways, nocturia, motor rigidity, RLS,
obstructive sleep apnea, rapid onset of sleep, nocturnal recurrence of PD symptoms, certain
medications, aging, anxiety and depression, and occurrence of muscle activity during REM sleep
which causes disturbed sleep and dream enactment during sleep.17,22,35 Studies suggest that some
sleep disorders may be present in patients before the manifestation of PD-related motor
symptoms and their frequency worsens with disease progression.36 Sleep-related disorders
among PD patients are associated with diminished sleep quality among caregivers, the
prevalence of which has been estimated as 20-60% across samples.37–40
Diagnosis and treatment of sleep disorders
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Sleep disorders are diagnosed either by using objective methods such as
polysomnography (PSG), multiple sleep latency test (MSLT) and maintenance of wakefulness
test (MWT), or by using subjective assessments such as self-rating scales.41 PSG assesses
nighttime sleep disturbances, while MSLT and MWT provide measures of wakefulness.41
Different rating scales measure different sleep-related constructs and are a popular choice
because they are inexpensive and relatively easy to administer in healthcare practice and research
settings.41
The most commonly used PD-specific rating scales for sleep are the Parkinson’s Disease
Sleep Scale Version 2 (PDSS-2) and the Scales for Outcomes in PD-Sleep (SCOPA-S).41,42 The
PDSS-2 is a 15-item questionnaire that measures nocturnal sleep disturbances and disabling
symptoms causing these disturbances.43 It has well-established psychometric properties and it
discriminates well between patients and non-diseased cohorts as well as patients at different
severity levels of sleep impairment.41–44 However, it uses a visual analog scale and might need
proper instructions before administration.41–44 The SCOPA-S has 12-items and measures overall
sleep impairment by assessing nocturnal sleep quality, sleep disturbances and daytime
sleepiness.45 It has good psychometric properties and can differentiate between presence/absence
of sleep impairment but not between the severity levels of impairment.41,42,44,45 It also does not
explore causes of disturbances and its responsiveness has not yet been established.41,42,44,45
The Pittsburgh Sleep Quality Index (PSQI) and the Epworth Sleepiness Scale (ESS) are
generic sleep measures that are routinely used across diverse populations.41,42 The PSQI is a 19item questionnaire that measures overall sleep impairment and other dimensions of sleep quality
but has certain limitations such as its propensity to recency effects and poor discriminant validity
among others.41,42 The ESS is an 8-item scale measuring presence and severity of daytime
5

sleepiness, however, it has an imprecise recall period and requires the caregiver’s assistance in
completing certain items.41,42
Some pharmacological interventions for sleep disorders have been evaluated in the
literature, however, MDS’s guidelines deemed only rotigotine, a dopamine agonist, as “likely
efficacious” for insomnia.9 Among non-pharmacological interventions, continuous positive
airway pressure has been indicated as “likely efficacious” to treat insomnia, excessive daytime
somnolence and sudden onset of sleep.9
Impact of sleep disorders in Parkinson’s disease
The impact of sleep disorders in PD is multidimensional. For patients, sleep disorders not
only have a significant negative impact on their HRQoL,23–25,33 but also on other NMS observed
in PD. For example, sleep disorders have a moderate effect on patient fatigue,46 and contribute
significantly to a patient’s mood disturbances38 and cognition.47 Enhanced sleep quality, on the
other hand, has been shown to improve working memory in patients, which is an indicator of
improved higher cognitive functioning involving planning, problem solving, delayed goal
execution and overall fluid intelligence.48
Moreover, studies have shown that some sleep disorders, such as insomnia, are also
prevalent among caregivers of PD patients.37–40,49,50 Caregivers’ own distress from caregiving
during the day or otherwise is one probable predictor.37 Further, Arber and Venn conducted indepth interviews and found that nocturnal caregiving responsibilities such as attending to
nocturnal physical needs of the patient, anticipation of nocturnal care needs, monitoring the
patient during sleep and the patient’s sleep disturbances may help explain sleep abnormalities in
caregivers.51 This negative influence of sleep disorders in patients on their caregivers’ burden
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was also seen in quantitative studies.19,39,49,52 Studies that have measured the impact of patients’
sleep on caregivers’ sleep and outcomes have often considered the individual (either the patient
or the caregiver) as the unit of analysis rather than take on a dyadic-oriented focus.
Dyadic analysis using the Actor-Partner Interdependence Model
The Actor-Partner Interdependence Model (APIM) is a methodology developed and used
extensively in psychological research to address data that involve mutual influence of thoughts,
emotions and behaviors between two persons involved in close relationships.53 The APIM is
used to analyze dyadic data where the effects of interest are of mixed variables, i.e., variables
that vary both between dyads and within dyads. The model has been increasingly used across
research domains such as emotion, healthcare, leisure activities, communication competence,
personality, commitment, interpersonal perception, relationship violence, social influence, and
attachment style.53 In healthcare, examples of studies that have used the APIM include those that
aimed to understand the relationship between anxiety and HRQoL with pediatric cystic fibrosis
patients and their caregivers,54 post-traumatic stress symptoms and HRQoL in chronically
critically ill patients and caregivers,55 and patient-physician shared-decision making on their
respective uncertainties of the decision being made.56 In PD, the model has been applied to
explore concepts such as benefit finding (i.e. experiencing personal growth after being faced
with a challenging situation)57 and relationship quality,58 emotional awareness, relationship
quality and satisfaction,59 and dyadic relationship and its psychosocial impact in patients and
their spousal caregivers.60 Given the model’s ability to account for interdependence in close
relationships, it provides a suitable methodology to examine the impact of sleep on HRQoL in
patient-caregiver dyads.

7

This model in Figure 1.1 below depicts two dyad members and two variables X and Y, for
each member in the dyad.53,61 X1 and X2 are scores on the predictor variable for dyad members 1
and 2, respectively. Y1 and Y2 are scores on the outcome variable for dyad members 1 and 2,
respectively. a denotes the actor effects (X1’s effect on Y1 and X2’s effect on Y2) and p denotes
partner effects (X1’s effect on Y2 and X2’s effect on Y1). The model allows for two correlations:
correlation between the X’s (represented by the curved line on the left) and correlation between
the Y’s (represented by the curved line on the right). This correlation between the Y’s is the
residual nonindependence between the outcome variables unexplained by APIM.

Figure 1.1: Actor-Partner Interdependence Model with actor and partner effects

Need for the study
Given the multifactorial ramifications of sleep disorders in PD patients and caregivers, it
is important to investigate this relationship to develop early detection strategies and appropriate
care opportunities. Several studies have evaluated this relationship, albeit with significant
limitations. Most studies evaluate the effect of patients’ clinical characteristics on their own
HRQoL or their caregivers’ HRQoL or caregiver burden independently. Specifically, in the
8

context of sleep disorders, the correlation or the nonindependence of patients’ and caregivers’
sleep quality is often ignored or one of the measurements is not collected. This may give rise to
biased variances and degrees of freedom in statistical significance tests, biased parameter
estimates, biased statistical significance tests and standardized effect measures, loss in precision
of estimates, and loss in power.53 These biased estimates lead to inaccuracies in estimating the
actual disease burden, and its spillover effects or the effect of the patients’ illness on their
caregiver/family. There is a need to implement appropriate statistical methodologies that account
for the dyadic nature of the patient-caregiver relationship when assessing the effect of sleep
disturbances on patients’ and caregivers’ HRQoL.
Specific aims
Considering previous literature and the above arguments, this study aimed to synthesize
existing literature on the impact of sleep disorders on the HRQoL of PD patients and their
caregivers, evaluate the psychometric properties of an HRQoL instrument in PD patients, and
finally, assess the dyadic relationship between sleep and QoL in PD patients and caregivers using
a conceptual framework. The specific aims of the study are as follows:
1. To conduct a systematic literature review to understand the relationship between sleep
and HRQoL among patients with PD and their caregivers.
2. To evaluate the psychometric properties and evaluate differential item functioning of
PROMIS-10 Global Health questionnaire in Parkinson’s Disease patients.
3. To assess the dyadic relationship between sleep and health-related quality of life in PD
patients and their caregivers using the Actor-Partner Interdependence Model (APIM).
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CHAPTER 2: RELATIONSHIP BETWEEN SLEEP AND HEALTH-RELATED
QUALITY OF LIFE AMONG PERSONS WITH PARKINSON’S DISEASE AND THEIR
CAREGIVERS – A SYSTEMATIC REVIEW
Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disease which manifests in
the form of motor symptoms and non-motor symptoms (NMS). Sleep disorders are the most
commonly occurring NMS among persons with PD (PWP), with a prevalence rate of ranging
from 40 to 90%.1–4 The most routinely reported sleep disorders among PWP include rapid eye
movement (REM) sleep behavior disorder (RBD), insomnia, nocturia, restless legs syndrome
(RLS)/periodic limb movement disorder (PLMD), sleep disordered breathing (SDB), excessive
daytime sleepiness (EDS), and circadian rhythm disorders.4 Several factors may contribute to
sleep disturbances in PWP including pathological degeneration of sleep regulation in the
brainstem and thalamocortical pathways, nocturia, motor rigidity, RLS, obstructive sleep apnea,
rapid onset of sleep, nocturnal recurrence of PD symptoms, dopaminergic therapy, certain
medications, aging, anxiety and depression, and occurrence of muscle activity during REM sleep
which causes disturbed sleep and dream enactment during sleep.2,5–8
Researchers argue that sleep disorders in PWP may be explained by multiple modalities
and that there is little evidence to indicate the correctness of one explanation over the others.9
Hence, there is a dearth of treatment options that specifically target sleep disorders in PD. The
International Parkinson’s and Movement Disorder Society’s Evidence-based Medicine
Committee synthesized available evidence on the safety and efficacy of interventions treating
PD-related sleep disorders such as continuous positive airway pressure, controlled-release
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formulation of levodopa/carbidopa, some dopamine agonists (pergolide, rotigotine, piribedil),
hypnotics (eszopiclone), melatonin, and psychoactive drugs (modafinil, and caffeine) and found
that only a few were “likely efficacious”, while most had “insufficient evidence” to be
recommended in routine use.10
As a result of the disease-related complications and a lack of targeted treatments, sleep
disorders contribute significantly to the overall disease burden among PWP and caregivers.
Several studies have highlighted the role of sleep disorders as a predictor of poor health-related
quality of life (HRQoL) in PWP,4,11–18 one of the most important outcomes of interest in chronic,
progressive and complex diseases such as PD. Compared to other NMS, nighttime sleep
disturbances and excessive daytime sleepiness, assessed using self-reported or clinician-reported
measures, have been shown to be significantly associated with both disease-specific,11,13,15,16,18–20
and generic HRQoL measures from patients.14,21 However, there are studies which found
contradicting evidence showing no significant relationship between sleep and HRQoL in
patients.12,25
Similarly, there are inconsistencies in the literature regarding the role of sleep in
caregiver HRQoL. Sleep disorders are very common among caregivers of PWP with estimated
prevalence rates of 20-60% across samples.23–26 Several factors may contribute to the
manifestation of sleep disorders in the caregiver, such as caregivers’ own distress from
caregiving during the day,23 attending to nocturnal physical needs of a patient, anticipation of
nocturnal care needs, monitoring a patient during sleep, and a patient’s sleep disturbances.27
While numerous studies have identified sleep disorders as a significant predictor of increased
caregiver burden or reduced HRQoL, other studies have shown a lack of support for this
relationship.25,28–32
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Despite the growth of research dedicated to understanding the role of NMS in PD,
knowledge regarding the impact of sleep disorders in PWP and caregivers remains unclear. An
enhanced understanding of this relationship is necessary to help advance the field of PD towards
identifying therapies or innovative care programs that can help alleviate the impact of sleep
disorders in PWP and their caregivers. Therefore, the current review aimed to critically and
systematically evaluate the literature on the association between sleep and HRQoL in PWP and
their caregivers.
Methods
A systematic review was conducted in accordance with the guidelines specified by the
Meta-analyses of Observational Studies in Epidemiology (MOOSE) group.33
Search strategy
To identify studies assessing the relationship between sleep and HRQoL in PWP and
caregivers, a literature search was conducted in June 2020 using the following databases:
Medline, EMBASE, CINAHL and PsychINFO. Key search terms related to PD, sleep and
HRQoL were mapped on to medical subject headings (see Table 2.1). A tailored search strategy
including medical subject headings combined with subheadings and related keywords was used
to capture as many studies as relevant to the current review. Truncated terms and Boolean
operators were used as appropriate to ensure coverage of keywords that begin with a given string
of text. A librarian was consulted during the development of the tailored search strategy in order
to ensure its accuracy and efficiency. Filters were used to search for studies conducted in human
subjects and published in English. Time period restrictions were not specified so as to include all
studies that fall under the scope of the current review. Grey literature search was done using
Google and Google Scholar. The protocol for the current systematic review was registered with
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PROSPERO (protocol ID: CRD42020201837), an international database of prospectively
registered systematic reviews in various fields where the outcome is related to health.34

Table 2.1: PubMed search terms for concepts relevant to the study objective
Concept

Search string
Parkinson’s Disease[MeSH Terms] OR Parkinson Disease[Tiab]

Parkinson’s disease

OR Paralysis Agitans[Tiab] OR Idiopathic Parkinson Disease[Tiab]
OR Primary Parkinsonism[Tiab]
Sleep*[tiab] OR “Sleep Wake Disorders” OR restless leg*[tiab] OR
dyssomn* OR parasomn*[tiab] OR narcolep* OR somnolen*[tiab]

Sleep disorders

OR hypersomn*[tiab] OR insomnolen*[tiab] OR hyposomn*[tiab]
OR myoclonus syndrome[tiab] OR hypnogenic paroxysmal[tiab]
OR somnamb*[tiab])

Health-related quality of life

Quality of life[MeSH Terms] OR Life quality[Tiab] OR Healthrelated quality of life[Tiab] OR HRQOL[Tiab] OR HRQL[Tiab]

Study selection
Inclusion criteria for studies was as follows: (1) included individuals diagnosed with
idiopathic PD, (2) are cross-sectional studies, (3) evaluated the relationship between sleep and
HRQoL in PWP or their caregivers or both, (4) full-text articles published in English.
Longitudinal studies assessing change in any of the variables of interest, studies evaluating
psychometric properties of scales related to the topic, and other reviews or expert commentaries
on the topic were excluded. Longitudinal studies which reported baseline measures of sleep and
HRQoL were included and only baseline data were considered in this review. Two of three
reviewers (Marie Barnard, Alexcia Carr and Sushmitha Inguva) screened the title and abstract of
19

each article obtained from the tailored search to identify studies that were eligible based on the
above criteria. Any discrepancies were resolved by a third reviewer. The reference section of
each article identified for full text review was reviewed to check for articles that may not have
been captured by the tailored search string. The attrition of articles excluded at each stage of the
review and reasons for exclusion are presented using the Preferred Reporting Items for
Systematic reviews and Meta-Analyses (PRISMA) flow diagram (Figure 2.1).
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Identification
Screening

Screening

Identification

Figure 2.1: PRISMA flowchart showing article screened and included for systematic review
Records identified through database
searching
(n = 986)
−
−
−
−

PubMed (290)
EMBASE (587)
CINAHL (18)
PsychINFO (91)

Records identified through database
searching
(n = 986)
Records after duplicates
− PubMed (290)
removed
− EMBASE(n(587)
= 229)
− CINAHL (18)
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Records after duplicates
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(n
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Records
screened

Records excluded
(n = 643)

Included

Eligibility

Eligibility

(n = 757)

Records screened
(n = 757)
Full-text articles assessed for
eligibility
(n = 114)

Full-text articles assessed for
eligibility
Studies included
in qualitative
(n = 114)
synthesis
(n = 34)

Records excluded
Full-text
articles excluded, with
(n = 643)
reasons (n = 80)
−
−

−
−
−
−

Studies included in qualitative
synthesis
(n = 37)
Studies reporting PWP
HRQoL
(n = 31)

−

Studies reporting caregiver
HRQoL
(n = 3)
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Duplicates (8)
Did not report the relationship
between sleep quality and HRQoL
(42)
Measured sleep in a domain with
other NMS (18)
Longitudinal study design (4)
HRQoL was not the dependent
variable (5)
Sample combined PWP with other
conditions (2)
Article not available in English (1)

Data extraction and quality appraisal
A standardized electronic data extraction form was developed for the full text review to extract
key information relevant to the current review. Two reviewers (Alexcia Carr and Sushmitha
Inguva) independently conducted the data extraction. The following items were identified as key
information to be extracted from the studies based on the Joanna Brigg’s Institute’s (JBI)
guidelines for systematic reviews: (1) Study details: author, year, journal, funder(s), (2) Study
methods/characteristics: study design, setting, recruitment procedures, sample characteristics,
independent variables and how they were measured, (3) Variables: primary and secondary
outcome variables and how they were measured, (4) Data analysis methods including statistical
technique utilized, assessment for confounding etc., (5) Results and (6) Limitations.35 The data
extraction form was pre-tested with a few studies to ensure its validity to the aims of the current
review before proceeding to extracting data from all included studies. Consensus over
discrepancies between the reviewers were resolved through discussions with a third reviewer
(Marie Barnard). The quality of studies was appraised using the Joanna Briggs Institute Critical
Appraisal Checklist for Analytical Cross-Sectional Studies.35 The tool is presented in Table 2.2.
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Table 2.2: Quality appraisal form used in the systematic review based on the Joanna Briggs
Institute critical appraisal checklist for analytical cross-sectional studies
Quality appraisal criteria

Response

1. Were the criteria for inclusion in the sample clearly defined?
2. Were the study subjects and the setting described in detail?
3. Was the exposure measured in a valid and reliable way?
4. Were objective, standard criteria used for measurement of the

Yes/No/Unclear/Not
applicable

condition?
5. Were confounding factors identified?
6. Were strategies to deal with confounding factors stated?
7. Were the outcomes measured in a valid and reliable way?
8. Was appropriate statistical analysis used?
9. Overall appraisal

Include/Exclude/Seek
further info

10. Comments (including reason for exclusion)

Data synthesis
Data extracted from the included studies and their quality assessment are presented in
Tables 2.3–2.8 (presented at the end of this chapter). A narrative synthesis of the results is
presented below. A narrative synthesis refers to the synthesis of findings across multiple studies
included in a systematic review that primarily relies on the use of text to summarize, often
complemented by a series of tables.36–38 The goal is to present a narrative of the findings of
reviewed studies to guide the reader through information such as direction of effect,
inconsistencies across studies etc.36–38
Results
Search yield
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The initial electronic search yielded 986 published articles (Figure 2.1). After removing
duplicates and reviewing titles and abstracts, 114 were considered suitable for full-text review.
By applying a set of pre-defined inclusion and exclusion criteria as mentioned above, 34 articles
in total were identified for inclusion in the current systematic review. Of them, 31 studies
reported on PWP HRQoL, whereas 3 studies reported caregiver HRQoL. Characteristics of
studies that assessed HRQoL of PWP are summarized in Table 2.3 and those that assessed
caregiver’s HRQoL are summarized in Table 2.4.
Study characteristics
While most of the studies assessing PWP HRQoL used a cross-sectional design, four
articles reported sleep and HRQoL measures at the baseline from a prospective study (Table
2.3).16,39–41 All articles assessing PWP HRQoL had sample sizes in the range of 35-1221, with
the majority of the studies having a sample size of more than 100. Three studies enrolled more
than 500 PWP, two of which collected data through population-based studies or registries.20,39,42
Twenty-nine of the 31 PWP studies conducted consecutive sampling from hospitals and
movement disorders or neurology clinics. While Karlsen et al.11 used a population sample
recruited from the community and Ylikoski et al.42 used a national registry.
Among studies which measured caregiver HRQoL, all studies were cross-sectional and
had sample sizes between 40-75 (Table 2.4). Two of them conducted consecutive sampling,25,43
while all three recruited PWP-caregiver dyads through outpatient clinics for this purpose.
Sample characteristics
Most studies assessing PWP HRQoL reported the mean age of participants to be over 65
years, while one study also enrolled young-onset PWP (Table 2.3).44 Studies that reported
HRQoL of PWP mostly enrolled individuals with mild to moderate PD severity as measured by
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the Hoehn and Yahr (H&Y) staging assessment. However, four studies included individuals with
severe PD (H&Y stage 5) within their sample, although these individuals made up less than 5%
of the total sample.14,17,20 In studies that reported disease duration, most of the studies enrolled
participants with a mean disease duration of at least 5 years. Two studies reported individuals in
the earlier stages (within 5 years) of their diagnosis.39,41,45
Among studies that examined caregiver outcomes, the mean age of caregivers was
reported to be over 50 years (Table 2.4). Only one study reported the relationship between
caregivers and PWP where most caregivers were spouses, followed by children and siblings.46
Measurement of sleep
The studies included in this review used subjective, patient-reported sleep measures
(Table 2.3). Both generic and disease-specific sleep measures were utilized. Among diseasespecific measures, the Parkinson’s Disease Sleep Scale (PDSS) and the Scales for Outcomes in
Parkinson’s Disease (SCOPA)-sleep nighttime sleep disturbances and daytime sleepiness scores
were most commonly reported. Some studies reported other measures such as the United
Parkinson’s Disease Rating Scale (UPDRS) parts I47 and IV,48 the Medical Outcomes Study
sleep measure,14 and interview questions to elicit presence of sleep disturbances11,28,42 among
patients. Among generic scales, the Pittsburgh Sleep Quality Index (PSQI) and the Epworth
Sleepiness Scale (ESS) were commonly used to measure sleep disturbances and EDS. The PSQI,
the ESS and the Medical Outcomes Study – Sleep Scale (MOS-SS) were reported to measure
sleep among caregivers (Table 2.4).
Measurement of HRQoL
Studies that reported PWP’s HRQoL used measures that can be classified as health status,
health utility and well-being scales. The majority of the studies used either a generic or a disease-
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specific health status measure to measure HRQoL (Table 2.3). The most frequently used diseasespecific measure was the Parkinson’s Disease Questionnaire-39 (PDQ-39). Two studies also
used another disease-specific measure – the Parkinson’s Disease Quality of Life (PDQL)
scale.49,50 Among studies that used generic measures, three used the SF-36.14,41,51 Other studies
reported the EQ-5D,39 EQ-VAS,40 Nottingham Health Profile (NHP)11 and World Health
Organization Quality of Life Assessment for Older Adults (WHOQOL-OLD).52
Among caregivers, the SF-36,43 WHOQOL-BREF46 and McGill Quality of Life
Questionnaire (MQoL)25 were reported as HRQoL measures (Table 2.4).
Relationship between sleep and HRQoL among PWP
Results examining the relationship between sleep and HRQoL among PWP are provided
in Table 2.5. There was variation in results reported across studies. The majority of the studies
reported a significant impact of sleep on reduced HRQoL. However, two studies were identified
which showed lack of a significant relationship between PWP sleep and their own HRQoL.53,54
Some studies also showed the significant impact of one or more dimensions of sleep on HRQoL
rather than sleep quality in general. For example, Kuhlman et al. showed that while ESS was a
significant predictor of worse HRQoL, whereas SCOPA-sleep nighttime was not.16 On the other
hand, Naismith et al. noted that SCOPA-sleep nighttime was positively correlated with PDQ-39,
whereas SCOPA-sleep day was not.55
Further, some studies used structural equation modeling (SEM) to explore the complex
interrelated associations across several PD-related factors and their impact on PWP
HRQoL.40,49,56,57 In addition to sleep’s direct effect on HRQoL,56,57 these studies also pointed to
indirect effects through depression,49,56 fatigue,56 ADL40,56 and pain catastrophizing.57 Moreover,
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Lee et al. found significant indirect effects of disease severity, social support and pain on
HRQoL through sleep disturbances.56
Relationship between sleep and caregiver HRQoL
Results examining the relationship between sleep and HRQoL among caregivers of PWP
are provided in Table 2.6. Two of three studies identified in this review showed that sleep-related
problems were common among caregivers of PWP.25,43
Within studies reviewed, Bartolomei et al. showed that patient sleep was associated with
lower physical and mental health scores.43 Ozdilek et al. did not show a significant relationship
between PWP sleep and HRQoL.46 Cupidi et al.25 reported significant negative impact of
caregiver sleep on their own HRQoL.
Quality appraisal
Most included articles well-addressed quality appraisal criteria related to research
objectives and description of participant characteristics (Tables 2.7 for PWP studies and 2.8 for
caregiver studies). The majority of articles also provided a clear explanation of the study design
and recruitment strategies. All of the studies reporting caregiver outcomes used appropriate
statistical methods and accounted for confounders. Studies reporting PWP’s HRQoL applied
statistical analysis techniques as suited to the research objectives. Twenty-six of these studies
accounted for confounders statistically, while the remaining five studies did not control for
confounding at the study design nor at the analysis stages.52,55,58–60
Discussion
There has been an increasing interest in understanding the role of NMS in PD. Sleeprelated disorders are not only one of the most common NMS, but also present several challenges
in PD treatment and management. Despite the significant challenges posed by sleep disturbances
in PD, there is a lack of consensus on its role in relation to PWP/caregiver HRQoL and caregiver
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burden. Therefore, the current review focused on critically evaluating and synthesizing current
literature on the association between sleep and HRQoL among PWP and their caregivers.
Studies reporting HRQoL among PWP
Despite the heterogeneous nature of studies included in this review, the majority (29 of
31) found PWP’s sleep to be a significant predictor of their own HRQoL. Two studies failed to
show evidence in support of this relationship.53,54 One of the reasons contributing to this lack of
relationship could be study cohort-specific factors. For example, these two studies evaluated
cohorts of individuals who reported a disease severity level of H&Y stage less than 2,53,54
whereas the other studies enrolled PWP across all stages of the disease spectrum. Given that PD
severity is one of the important factors which predict the prevalence of certain sleep disorders,61–
65

the relative frequency of sleep disturbances and their intensity in these studies may have been

low.
In terms of sleep assessment, all studies provided self-reported measures of either PDspecific or generic measures of sleep among PWP. The dearth of studies using objective tools
such as polysomnography or actigraphy is not surprising given the well-established, robust
psychometric properties of these self-reported measures as well as practical considerations such
as time and economic constraints in routine clinical practice. The PDSS/PDSS-2 was the most
commonly used disease-specific measure. Most other studies included separate measures for
nocturnal and diurnal sleep symptoms in their analyses. Among such studies, the results were
somewhat ambiguous as some identified both nighttime and daytime sleep measures as
significant predictors of HRQoL,14,15,18,20,39,50,60,66,67 whereas some identified only nighttime55 or
daytime16,17,40,45,68 sleep symptoms as significant contributing factors to HRQoL among PWP.
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Further, most included studies conducted multivariable analytic methods to account for
confounding factors. Multivariable ordinary least squares regression with HRQoL as the
dependent variable was the most common choice among studies reviewed, while 5 of 31 studies
merely reported bivariate analyses.52,55,58–60 It is worth noting that there were four studies which
utilized SEM in order to develop comprehensive, structural models that account for the complex
interrelationships among several predictors of HRQoL simultaneously.40,49 Significant,
meaningful findings from these studies make a strong argument for use of such methods which
may be better equipped to explain the multifaceted relationships encountered in PD.
Studies reporting HRQoL among caregivers
This review yielded three studies which measured caregiver-reported outcomes, which
explored diverse research questions. One study evaluated the association between caregiver’s
sleep and caregiver HRQoL and found a significant relationship.25 Another study evaluated the
impact of PWP’s sleep on caregiver outcomes and did not find a significant relationship.46 The
other study evaluated several relationships – the impact of PWP’s sleep on caregiver’s sleep,
HRQoL and burden, respectively, as well as the impact of PWP’s HRQoL on caregiver’s
HRQoL and burden, respectively.43 It is interesting to note that while all these studies recruited
PWP-caregiver dyads and collected data from both members, none of the studies accounted for
the interdependent nature of the constructs. Specifically, the bidirectionality of sleep
disturbances and their mutual influence on each dyad member’s HRQoL in PWP-caregiver dyads
have been ignored. Future studies should probe into this complicated phenomenon to better
understand the scope of sleep disturbances and their role in the PWP-caregiver dynamic.
Moreover, the role of depression as a mediator of the relationship between sleep and their
HRQoL, specifically the psychological symptoms domain, has been highlighted.25 This
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relationship was also reported in some of the PWP studies we reviewed in the context of PWP
sleep and HRQoL as well.49,56 There is some literature supporting depression or the broader
mental well-being domain as a mediator in this path model in older adults, regardless of disease
state.69,70 However, there is also evidence that suggests sleep quality may in fact mediate the
relationship between depression and quality of life in older adults.71 There is a need for more
empirical evidence, preferably from longitudinal studies, to evaluate the temporality and
reproducibility of these results.
In accordance with the objective for this review to identify studies evaluating the impact
of either PWP or caregiver’s sleep on caregiver HRQoL, three studies which focused on
caregiver HRQoL were identified.25,43,46 However, while reviewing the articles, three other
studies were identified which measured caregiver burden as an outcome.28,29,32 Data extracted
from these three studies are reported in the Appendix. Given the strong correlation between
caregiver burden and HRQoL,72–75 future studies may consider reviewing studies which have
assessed the impact of PWP or caregiver’s sleep on caregiver burden.
Limitations
There are some limitations to bear in mind while viewing these results. First, a majority
of the studies that measured caregiver outcomes had low sample sizes. Consequently, the results
may not be generalizable to the larger PD population. Second, this review only included crosssectional studies and hence, results are limited to correlations between variables of interest.
However, this review lays the groundwork for future research aiming to gain a better
understanding of sleep patterns and their impact on humanistic outcomes in PWP and their
caregivers. A review of longitudinal studies is warranted to generate evidence supporting causal
inferences.
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Conclusion
To our knowledge, this review is the first to summarize existing literature on the
importance of sleep in the context of humanistic burden among PWP and their caregivers.
Empirical evidence suggests that sleep-related issues have a significant impact on HRQoL
among PWP. There is a need for more studies evaluating the impact of PWP or caregiver sleep
on caregiver HRQoL. A review of studies assessing caregiver burden is required to better
understand the impact of PWP or caregiver’s sleep on caregivers.
Implications for clinical practice
In clinical practice, it is recommended that the input of the caregiver or the bed partner be
sought for a more objective assessment of PWP’s sleep and wakefulness behaviors.76 However,
at present there is no guidance on screening caregivers for sleep-related issues. Healthcare
professionals may consider initiating conversations related to sleep issues with caregivers during
a clinic visit, followed by either treatment initiation or referrals to specialist health services,
whichever is appropriate. There are several non-pharmacological interventions such as use of
melatonin supplements, practicing meditation and mindfulness techniques, and incorporating
physical activity into daily routines that may help alleviate some sleep symptoms and improve
HRQoL. Additionally, in case of co-occurrence of sleep disorders in PWP-caregiver dyads,
optimization of anti-Parkinsonian or sleep medications to reduce symptom burden may be
considered which may prove to be beneficial for both members of the dyad. Finally, sharing
caregiving responsibilities with another informal or hired caregiver and seeking respite care
services may also be considered to reduce the burden of sleep issues among caregivers.
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Table 2.3: Methodological characteristics of included studies that reported health-related quality of life of persons with
Parkinson’s disease
Study design

Participant characteristics

Author,

Design

Recruitment
method

Source of
participants

Sample
size

Country

Andreadou et
al.48

CS

Consecutive

2011

Outpatient
clinic of a
Neurology
Department

139

Neurologist
clinics

371

Age in
years
(Mean ±
SD)
69.6 ± 9.1

Female
(%)

H&Y stage

in years
(Mean ±
SD)

51

Range: 4289

Mean = 2.1,

8.5 ± 6.2

SD = 0.8
32

Publication
Year,

Disease
duration

Greece
Avidan et al.14
2013
US

CS

Population

72.2 ± 9.2

4.5

Stage 0 (0),
4.6 ± 2.2
stage 1
(7.8%), stage
1.5 (4.6%),
stage 2
(32.7%),
stage 2.5
(29.4%),
stage 3
(19.0%),
stage 4
(3.9%), stage
5 (2.6%)

Neurology
and elderly
care clinics in
hospitals
based in
several
locations
across the UK

769

UK

PS
NR
(baseline
measures
were
reported
in the
study)

Fan et al.53

CS

Outpatient
clinics of a
movement
disorder
specialist

134

2015

NR

2016
Taiwan

Gallagher et
al.17

67.7 ± 9.5

33.9

Stage 0 (0),
1.3 ± 1.0
stage 1
(23.3%),
stage 2
(69.3%),
stage 3
(7.5%), stage
4-5 (0)

36.6

Mean =
1.43, SD =
0.64

7.86 ± 5.55

Range: 3289

64.89 ±
9.19
Range: 4187

CS

NR

Three
different
hospitals

89

67.5 ± 9.5

31

Stage 1 (n =
1), stage 2 (n
= 56), stage
3 (n = 29),
stage 4 (n =
5), and stage
5 (n = 3)

7.8 ± 7.5

CS

Consecutive

Movement
Disorders
Unit of a
hospital

99

NR

NR

NR

8.7 ± 6.3

2010
UK

GómezEsteban et al.13
2010
Spain

Range: 0-23
33

Baig et al.39

Havlikova et
al.18

CS

NR

2011

1 hospital and
18 outpatient
departments

93

Patients
with H&Y
≤ 2: 67.8 ±
9.23

Patients
with H&Y
≤ 2: 49.3%

NR

Patients
with H&Y ≤
2: 5.43 ± 4.3

Slovakia
Patients
with H&Y
> 2: 70.3 ±
10.8
NR

Movement
Disorders
Clinic

110

65.13 ±
9.23

24.5

H&Y during
"off" time:
Mean =
2.58, SD =
0.69

5.58 ± 3.52

Population

County of
Rogaland

233

73.6 ± 8.4

51

Mean = 2.9,
SD = 1.1

6.3 ± 5.3

Movement
disorders
clinic

102

68.2 ± 10.1

39.2

NR

68.2 ± 10.1

2015
Israel

Karlsen et al.77

CS

Patients
with H&Y >
2: 8.06 ± 5.2

1999

34

Herman et al.58 CS

Patients
with H&Y
> 2: 57.1%

Norway
Kuhlman et
al.16
2019
US

PS
NR
(baseline
measures
were
reported
in the
study)

Lee et al.49

CS

NR

2014
Korea

Neurology
outpatient
department of
a tertiary
hospital

217

<65: N = 94 52.1
(43.3%)

NR

6.63 ± 5.31
Range: 0.0830.0

65-74: N =
83 (38.2%)

Lee et al.56

CS

Convenience

Inpatient and
outpatient
neurologic
clinic of a
tertiary
hospital

248

65.82 ±
9.07

60.1

CS

NR

Tertiary
neurology
setting

103

65.03 ±
8.98

42

CS

Consecutive

Movement
Disorders
Clinic

57

70.3 ± 6.8

47

2018
Korea

Lerman et al.57
2019

Modified
7.62 ± 4.58
H&Y stage:
Mean =
2.64, SD =
0.80, Median
=3

6.98 ± 4.96

Israel
Margis et al.52
2010
Brazil

Range: 6086

NR

7.5 ± 5.8
Range: 1-31

35

≥75: N = 40
(18.4%)

Naismith et
al.55

CS

NR

2010

Parkinson’s
Disease
Research
Clinic

35

Outpatient
facilities

272

NR

48

63.91 ± 7.6

45.7

Range: 4285

Mean = 2.2,
SD = 0.6

5.8 ± 5.3

NR

7.3 ± 5.8

Range =1–
20

Australia
Nicoletti et
al.59

CS

NR

2017

66.2 ± 9.4,
Range: 3789

65

Bad
Sleepers:
71.00 ±
5.50

NR

Range: 1-40

Italy
CS

NR

2019
Italy

NR

Good
sleepers
11.43 ± 7.82

Good
sleepers:
68.38 ±
5.77

Pandey et al.60

2016
India

CS

NR

Department
of Neurology
of tertiary
care teaching
institute

100

59.2 ± 9.06

Bad sleepers
10.04 ± 5.53
36

Palmeri et al.66

25

Stage 1-2
(mild PD) (n
= 65), stage
2.5-3
(moderate
PD) (n =
29), stage 4-

44.87 ±
44.06 (in
months)

5 (severe
PD) (n = 6)

CS

NR

2018
Republic of
Korea

Movement
132
disorder clinic
at 5 university
hospitals

Youngonset PD:
49.1 ± 3.3

Middleonset PD:
61.7 ± 5.5

Late-onset
PD: 74.6 ±
3.6

Youngonset PD:
46.2

NR

(in months)

Young-onset
PD: 27.5 ±
15.6

Middleonset PD:
60

Middleonset PD:
14.3 ± 11.0

Late-onset
PD: 50

Late-onset
PD: 13.8 ±
9.6

Qin et al.41
2009
China

RCT
Population
(baseline
measures
were
reported
in the
study)

Movement
Disorder
Clinics

391

63.77 ±
9.80

34.5

Mean =
2.00, SD =
0.70

2.98 ± 1.92

37

Park et al.44

Semiz et al.50

CS

NR

Movement
120
disorder clinic

67.8 ± 12.5

30

Stage 1: 15
(12.5%),
stage 2: 46
(38.3%),
stage 3: 27
(22.5%),
stage 4: 32
(26.7%)

4.7 ± 4.9

CS

NR

Movement
Disorder
Centers

Mean age =
68, SD =
9.0

46.4

NR

NR

44.6

Mean =
2.70, SD =
0.77

12.84 ± 2.92

2007
Turkey

Skorvanek et
al.47

38

2015

291

Slovakia
Median age
= 70

Range: 30 88

Sun et al.68
2018
China

CS

NR

Movement
disorder
specialist
clinic

121

66.46 ±
8.57

Tibar et al.54

CS

NR

Department
117
of Neurology
and
Neurogenetics
in a university
hospital

60.77 ±
11.36

44.4

H&Y stage
> 2 (27.3%)

NR

CS

NR

Movement
Disorders
Clinic

69 ± 11

46.7

“Off” time:
Mean = 2.7,
SD = 0.7

9±6

2018
Morocco

Vila Cha et
al.51
2019

229

UK

Visser et al.40

39

“On” time:
Mean = 2.3,
SD 0.5
University
and regional
hospitals

378

60.0 ± 11.2

33.9

NR

NR

UK

PS
NR
(baseline
measures
were
reported
in the
study)

Walton et al.67

CS

Parkinson's
Disease
Research
Clinic

203

66.77 ± 8.9

32

Stage 1 (n =
39), stage
1.5 (n = 7),
stage 2 (n =
98), stage
2.5 (n = 39),

61.3 ± 61.3
(in months)

2008

2014
Australia

NR

Xiang et al.20

CS

NR

Clinic or
inpatient
department of
Department
of Neurology

1221

61.5 ± 9.9

45.9

Stage 1: 178 5.1 ± 4.5
(14.6%),
stage 1.5:
161 (13.2%),
stage 2: 268
(21.9%),
stage 2.5:
231 (18.9%),
stage 3: 314
(25.7%),
stage: 53
(4.3%), stage
5: 16 (1.3%)

CS

Registry

Finnish
Parkinson
Association
Registry

684

67.8 ± 8.7

54.1

NR

2019
China

Ylikoski et
al.42
2017
Finland

6.1 ± 5.0

40

stage 3 (n =
20)

Yoo et al.45

CS

NR

University
hospital

198

69.1 ± 9.7

52

Mean = 1.8,
SD = 0.7

0.9 ± 1.4

CS

NR

Neurology
outpatient
clinics

211

64.08 ±
9.44

44.6

Mean =
2.25, SD =
0.84

6.02 ± 4.53

2019
Korea

Yu et al.15
2015

41

Taiwan

H&Y = Hoehn & Yahr, CS = Cross-sectional, SD = Standard deviation, NR = Not reported, PS = prospective, PD = Parkinson’s disease, RCT = Randomized
controlled trials

Table 2.4: Methodological characteristics of included studies that reported health-related quality of life and/or caregiver
burden of caregivers of persons with Parkinson’s disease
Author,

Study design

Publication Year,
Design
Country
Bartolomei et al.43

Recruitment
method

Participant characteristics
Source of
participants

Sample size

Age in years
Female (%)
(Mean ± SD)

Relationship to
care recipient

CS

Consecutive

Multiple
hospital clinics

75

62.0 ± 12.0

48

NR

CS

Consecutive

Neurology
clinic

40

64.2 ± 9.4

70

NR

CS

NR

Neurology
clinic

50

56.6 ± 13.2

78

Spouse (74%),
Children (22%),
Siblings (4%)

2018
Italy
Cupidi et al.25

42

2012
Italy
Ozdilek et al.46
2012
Turkey

CS = Cross-sectional, SD = Standard deviation, NR = Not reported, PS = prospective

Range: 20-85

Table 2.5: Sleep and health-related quality of persons with Parkinson’s disease
Author,
Publication
Year,

Sleep measurement tool
& score

HRQoL measurement tool
and score

Mean ± SD

Mean ± SD

HRQoL results

Study limitations

− Selection bias
introduced due to
exclusion of more
severe patients
(H&Y stage 5)

Andreadou et
al.48

UPDRS Part IV sleep
disturbances: 43 of 139
patients reported sleep
disturbances (30.9%)

PDQ-39 summary index: 22.1
± 18.2

Sleep disturbances were
significantly associated with
lower HRQoL.

Avidan et al.14 MOS sleep measure
domains – Sleep
2013
disturbance (initiation):
21.8 ± 25.6
US

SF-36 v.2 measure domains –
Physical functioning: 36.8 ±
11.5

Sleep disturbance
(initiation), awakening short
of breath or with headache,
daytime somnolence were
significant negative
predictors of SF-36 v.2 PCS.

2011
Greece

Sleep disturbance
(maintenance): 34.9 ±
24.5
Awakening short of
breath or with headache:
9.8 ± 20.0
Daytime somnolence:
39.7 ± 20.7
Sleep inadequacy: 40.8 ±
26.8
Snoring: 37.3 ± 33.4

Physical role limitations: 39.1
± 11.2
Emotional role limitations:
42.7 ± 11.9
Pain: 46.3 ± 10.9
Emotional well-being: 48.0 ±
10.3
Energy: 45.9 ± 11.2
General health: 42.0 ± 9.3
Social functioning: 44.3 ±
10.3

− Cross-sectional
study; cannot
determine
causality
− Lack of objective
measures of sleep
− MOS sleep
measures were
not on Movement
Sleep disturbance (initiation)
Disorders Society
and awakening short of
taskforce review
breath or with headache were
of sleep measures
significant predictors of SF36 v.2 MCS.

43

Country

SF-36 v.2 composite scores –
Physical: 39.2 ± 10.0
Mental: 48.3 ± 11.0

2015

Daytime somnolence
(ESS): Median (IQR): 7
(4-10)

EQ-5D: scores not reported

UK
RBD (RBDSQ): Median
(IQR): 4 (2-7)

Fan et al.53

PDSS-2: 18.36 ± 16.72

PDQ-39: 37.99 ± 25.40

2016

Range: 1-72

Range: 0-135

Taiwan

− Residual
confounding
− Recall bias
− Potential bias of
mobility,
comorbidity,
cognition and
social constraints
among
nonparticipants
PDSS-2 was not a significant − Brief self-report
scales prohibited
predictor of worse HRQoL.
from clarifying
nature of mood
disorders
− Cross-sectional
study; cannot
determine
causality
− Psychiatristbased interviews
may help
elucidate types of
mood disorders
that may impact
HRQoL
Sleep disturbance, daytime
somnolence and RBD were
significant predictors of
worse HRQoL.

44

Baig et al.39

2010

PSQI, ESS, SCOPA sleep
night, SCOPA sleep
daytime: scores were not
reported

PDQ-39: score not reported

PDSS: 108.9 ± 14.6, 95%
CI: (102.9, 110.0)

PDQ-39: 24.7 ± 13.2, 95% CI:
(22.1, 27.4)

UK

GómezEsteban et
al.13
2010
Spain

ESS: 8.6 ± 4.3, 95% CI:
(7.9, 10.1)

Two regression models were − Use of selfreported
conducted – model 1
questionnaires
(included clinical scale
(potential undersummary indices only) and
representation of
model 2 (included clinical
patients with
scale summary indices and
cognitive
autonomic subscales):
impairment and
SCOPA sleep daytime was a
apathy)
significant predictor of worse
− Selection bias
HRQoL in both models.
arising due to
inclusion of
patients at
movement
disorder clinics
who may have
achieved
optimization of
therapy
− Motor scores
assessment in
“on” state may
lead to less
between-patient
variability
Stepwise linear regression
− Use of MMSE
which has low
model identified four
sensitivity for
variables (in order of
detecting
importance: NPI, PDSS,
cognitive
UPDRS IV and UPDRS I)
deterioration
accounting for 67.2% of the

45

Gallagher et
al.17

Havlikova et
al.18
2011
Slovakia

PSQI:
H&Y ≤ 2 group: 8.6 ± 4.8
H&Y > 2 group: 10.2 ±
4.7

PDQ-39:
H&Y ≤ 2 group: 29.9 ± 17.9
H&Y > 2 group: 51.1 ± 17.8

PSQI and ESS were both
significant predictors of
worse HRQoL.

ESS:
H&Y ≤ 2 group: 7.1 ± 4.4
H&Y > 2 group: 9.1 ± 5.6
Herman et
al.58
2015
Israel

PSQI: scores were not
reported

PDQ-39:
PIGD group: 21.75 ± 12.25
TD group: 20.84 ± 14.90
p-PIGD group: 26.28 ± 12.46
p-TD group: 16.93 ± 12.22

PSQI was significantly
correlated with lower PDQ39.

− Low response
rate
− Sample may not
be representative
of patients
outside of
outpatient clinics
and those with
higher disease
severity levels
− Use of generic
instruments for
sleep
− Cross-sectional
study; cannot
determine
causality
− Patients with
dementia were
excluded
− NMSQuest was
assessed which
has a recall
period of a month
which
encapsulated
“on” and “of”
periods.

46

variance in PDQ-39
summary index.

Karlsen et
al.77
1999

Presence of nocturnal
sleep disturbances
(60.3%)

NHP: 137.1 ± 97.3

NHP subdimensions –

Norway

Emotional reactions: 13.1 ±
17.0

Presence of nocturnal sleep
disturbance was a significant
predictor of lower total NHP
and subdimensions including
physical mobility, sleep and
social isolation.

− None reported

Energy: 26.3 ± 33.3
Pain: 22.0 ± 24.6
Physical mobility: 41.2 ± 31.7
Sleep: 27.2 ± 28.4

Kuhlman et
al.16

SCOPA-Sleep NS:
Median (IQR): 4 (2-7)

PDQ-39: Median (IQR): 13.6
(7.9-20.7)

2019
US

ESS: Median (IQR): 8 (513)

Lee et al.49

RCSQ: 18.09 ± 5.30

PDQL: 130.83 ± 29.43

2014

Range: 5-25

Range: 56-183

Korea

47

Social isolation: 20.4 ± 23.6
− Cross-sectional
study; cannot
determine
causality
− Not generalizable
to more advanced
PD and other
sub-populations
− Factors such as
social support
and exercise were
not measured
Quality of sleep did not have − Results are not
generalizable to
a significant direct effect, but
patients with
had an indirect effect on
cognitive
impairment and
ESS was a significant
predictor of worse HRQoL,
while SCOPA-sleep NS was
found not to be significant.

Lee et al.56

PDSS: 100.13 ± 29.42

PDQ-39: 33.16 ± 19.63

2018
Korea

Lerman et
al.57
2019
Israel

PDSS: scores were not
reported

PDQ-39: scores were not
reported

Sleep disturbances had a
significant direct effect and
indirect effect on HRQoL
through depression, fatigue
and ADL. Disease severity,
social support and pain had
indirect effects on HRQoL
through sleep disturbances.

−

Sleep disturbances (PDSS)
had significant direct and
indirect (through pain
catastrophizing) effects on
HRQoL.

−

−

−

−

−

those with higher
disease severity
levels
UPDRS III was
not measured
PDQ-39 items
partially
overlapped with
several variables
such as mobility,
ADL, bodily
discomfort and
emotional wellbeing
Inflated shared
variance due to
the use of selfreport
questionnaires
Other factors
such as sexual
dysfunction and
autonomic
abnormalities
were not assessed
Sample included
persons without
severe cognitive
impairment
Cross-sectional
study; cannot
determine
causality

48

HRQOL, through
depression.

Margis et al.52

PSQI: 9.3 ± 4.6

2010
Brazil

WHOQOL-OLD total: 63.9 ±
14.0

ESS: 7.8 ± 4.4
WHOQOL-OLD domains –
PDSS: 91.5 ± 29.7

Sensory capabilities: 60.8 ±
23.7
Autonomy: 61.3 ± 16.4
Past, present and future
activities: 66.0 ± 18.4

WHOQOL-OLD domains
sensory capabilities and
autonomy were correlated
significantly with sleep
measures. Specifically,
sensory capabilities showed
a negative association with
PSQI and a positive
correlation with PDSS
scores, whereas those for
autonomy showed an inverse
association with PSQI.

− No comparator
groups
− Small sample size
(N = 57)
− Not generalizable
to PD patient
population at
large

SCOPA-sleep night was
positively correlated with
PDQ-39, whereas SCOPAsleep day was not
significantly correlated.

− Small sample size
(N = 35)
− Disease severity
ranged from mild
to moderate
− Difficult to
dissect complex
interrelated
multifactorial
relationships in a
small clinical
study

49

Social participation: 58.3 ±
20.8
Death & dying: 67.5 ± 25.2
Intimacy: 70.2 ± 20.2
Naismith et
al.55

SCOPA-sleep day: 5.00 ±
3.30

2010

Range: 1-13

Australia
SCOPA-sleep night: 6.46
± 4.00
Range: 0-15

PDQ-39: 38.60 ± 27.60
Range: 5-98

PDSS: scores were not
reported

PWS: 348.72 ± 46.12
Range: 222-454

2017
Italy

Domains –
Autonomy: 60.18 ± 8.60,
Range: 35-84
Environmental mastery: 56.98
± 9.51, Range: 32-83
Personal growth: 55.74 ± 8.22,
Range (28-80)

A direct correlation was
found between PWS total
score and PDSS total score.
PDSS was also significantly
correlated with all domains
of PWS.

− Cross-sectional
study; cannot
determine
causality
− Study sample
mainly comprised
of patients in the
early stages of
the disease
− Uninvestigated
factors
contributing to
PWS total score
variability
50

Nicoletti et
al.59

Positive relations: 60.03 ±
10.21, Range: 26-83
Purpose in life: 57.33 ± 9.56,
Range: 28-78
Self-acceptance: 58.46 ±
10.65, Range: 19-82

PDQ-39: scores were not
reported
Palmeri et
al.66
2019
Italy

PSQI:
Bad sleepers (PSQI > 5):
11.78 ± 4.05

PDQ-39: Total: Bad sleepers:
37.63 ± 16.37
Good sleepers: 31.69 ± 10.33

Backward linear regression
− Small sample size
(N = 48)
in bad sleepers group
− Use of
showed ESS to be a
antidepressants
significant predictor of worse
and sleep therapy

Pandey et al.60 PSQI:

2016
India

Poor sleepers (PSQI > 5):
50% patients

PDQ-39 summary index
score:
Poor sleepers: 20.14 ± 15.19

Good sleepers (PSQI ≤ 5): Good sleepers: 27.20 ± 16.41
50% patients

ESS:
Poor sleepers: 5.18 ± 3.45
Good sleepers: 5.34 ±
4.38

cognition and bodily
discomfort, respectively.

were not
considered

Backward linear regression
in bad sleepers group
showed ESS and PSQI each
to be significant predictors of
worse ADL; ESS as a
significant predictor of
higher stigma, worse
cognition, respectively; and
PSQI as a significant
predictor of communication.
Both PSQI and ESS were
correlated with poor
HRQoL. Compared to good
sleepers, patients with poor
sleep quality had worse
HRQoL as determined by
PDQ-39 summary index
scores.

51

Good sleepers (PSQI ≤ 5): Domains: Mobility, ADL,
0.76 ± 1.30
emotional well-being, stigma,
social support, cognition,
communication and bodily
discomfort were not
ESS:
significantly different between
Bad sleepers: 8.59 ± 2.94 bad and good sleeper groups.
Good sleepers: 3.24 ±
2.02

− Use of generic
sleep scale

PDSS:

PDQ-39:

2018

YOPD: 127.4 ± 19.3

YOPD: 4.4 ± 7.6

Republic of
Korea

MOPD: 127.8 ± 19.7

MOPD: 14.3 ± 12.4

LOPD: 128.3 ± 19.2

LOPD: 12.6 ± 11.2

Qin et al.41

PSQI: 7.60 ± 8.60

SF-36: 63.76± 19.39

2009

With sleep problem group:
57.68 ± 19.65

China

Sleep was a significant
predictor of worse HRQoL
in the MOPD group.

Patients without sleep
problems had significantly
higher HRQoL than patients
with sleep problems.

− Did not enroll
age-matched
controls
− Higher frequency
of comorbidities
and medications
for these diseases
in LOPD
− Mostly enrolled
early stage
patients therefore,
advanced
symptoms could
not be assessed
− Use of generic
QoL instrument
− Limited
generalizability

Without sleep problems
group: 71.17± 16.30
Semiz et al.50

PDSS: 88.7 ± 32.1

PDQL: 76.2 ± 25.3

In stepwise regression
analysis, PDSS and PSQI
were found to be
significantly associated with
worse PDQL scores.

− Lack of a control
group
− Recall bias
− Lack of use of
polysomnography
to assess sleep

PDQ-39: Summary index:
36.7 ± 19.7

In a multiple regression
analysis model worse
HRQoL as measured by the

− More motivated
patients agreed to
participate and
were able to

2007
Turkey

PSQI: 9.0 ± 4.1

ESS: 7.3 ± 5.4
Skorvanek et
al.47

UPDRS part I: 14.0 ± 7.6
Median = 13
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Park et al.44

Range: 2-40

Slovakia

Sun et al.68

Median = 37.2
Range: 0-85

PDSS: 98.79 ± 26.83

PDQ-39: 29.98 ± 17.80

ESS was a significant
predictor of worse HRQol.

Neither PSQI nor ESS had a
significant impact on
HRQoL.

2018
China

ESS: 8.40 ± 6.24

Tibar et al.54

PSQI: 9.48 ± 4.72

PDQ-39: 25.83 ± 16.54

2018

Median (IQR): 8 (6-12)

Median (IQR): 23.22 (13.3636.69)

Morocco
ESS: 6.38 ± 5.35
Median (IQR): 5 (2.289.80)

PDQ39 summary index was
attend the
examination
significantly related to the
MDS–UPDRS parts I, II and − Does not
establish
IV, respectively. Within
causality
domains, PDQ-39 emotional
− Cannot
well-being was associated
generalize the
with sleep problems and
results
PDQ-39 cognition was
related to daytime sleepiness.
− Cross-sectional
study; cannot
determine
causality
− Descriptive in
nature
− Patients with
disease duration
≥ 10 years were
evaluated during
the “on” state
− Low disease
severity (27.3%
had H&Y score
>2)
− Patients with
dementia were
excluded
− Cross-sectional
study; cannot
determine
causality
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2015

Vila Cha et
al.51

PDSS-2: 15 ± 10

SF-36 physical and mental
health scores were
significantly lower in group
2 compared to group 1.

− Recruitment was
consecutive, but a
significant
number of
subjects were
unable to
complete parts of
the protocol due
to impaired
cognition
− Use of selfreported
questionnaires for
sleep

EQ-VAS: 67.8 ± 14.2

SCOPA-sleep DS had a
significant indirect
relationship on HRQoL
through ADL.

PDQ-39: 21.21 ± 14.0

Both SCOPA-sleep day and
SCOPA-sleep night were
significant predictors of
worse HRQoL.

− Selectively
excluded patients
with too many
missing values
− Stratification on
age at onset and
disease duration
may make the
cohort less
representative of
PD community
− Use of selfreported
measures
− Use of a more
detailed cognitive

SF-36 physical health:

2019

Group 1 (PDSS-2 < 18):
Median (IQR): 42 (33-51)

UK

Group 2 (PDSS-2 ≥ 18):
Median (IQR): 32 (28-42)

SF-36 mental health:
Group 1 (PDSS-2 < 18):
Median (IQR): 50 (41-57)
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Group 2 (PDSS-2 ≥ 18):
Median (IQR): 43 (34-49)
Visser et al.40
2008

SCOPA-sleep NS: 4.4 ±
3.7

UK
SCOPA-sleep DS: 4.7 ±
3.7

Walton et al.67 SCOPA-sleep day: 4.29 ±
3.5
2014
Australia

Xiang et al.20

ESS: 7.6 ± 6.1

PDQ-39: 30.1 ± 24.7

PDQ-39 score was found to
be a significant predictor of
worse EDS (ESS).

Self-rated health (SRH):

WHO5 was a significant
predictor of sleep
deprivation.

2019
China

PDSS: 116.9 ± 24.8

RBD: reported in 36.9%
of patients
Ylikoski et
al.42

Short sleepers (≤6 hours):
126 (26.2%) patients

2017
Finland

Long sleepers (≥9 hours):
192 (32.5%) patients

Poor SRH: 301 (44.4%)
patients

WHO5:
Poor QoL (WHO5 < 52): 290
(43.3%) patients

assessment (vs.
MMSE) may
have influenced
the model in
favor of strong
impact of
cognition on
HRQL
− Higher
proportion of
males (typical of
the disease)
− Lack of
subjective
measures to
assess sleep
disorders
− Cross-sectional
study; cannot
determine
causality
− Self-reported data
causing possible
misclassification
in some
participants
− Data on
cumulative
lifetime dose for
dopaminergic
medication were
not available
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SCOPA-sleep night: 4.67
± 4.2

− Cross-sectional
study; cannot
determine
causality
− Some items were
assessed using
only one question

Poor sleepers (sleep
efficiency < 80%): 115
(21.2%) patients

Sleep deprivation: 173
(33.8%) patients

Disrupted sleep: 305
(47.4%) patients

Yoo et al.45

PDSS-2: 13.6 ± 7.2

2019
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Difficulties to fall asleep:
83 (12.2%)
Korean version of PDQ-39:
Non-EDS group: 20.3 ± 12.3

Korea

ESS: 6.5 ± 5.7

EDS group: 37.2 ± 16.1

Yu et al.15

ESS: 5.85 ± 5.04

PDQ-39: 37.64 ± 26.64

2015
Taiwan

PSQI: 7.23 ± 3.51

Good sleepers (PSQI ≤5):
27.11 ± 22.28
Poor sleepers (PSQI >5):
43.79 ± 27.53

PDSS-2:

PDQ-39 scores were
significantly higher (worse
HRQoL) in the EDS group
compared to the non-EDS
group.
Pain in arms or legs, daytime
dysfunction, uncomfortable
immobility at night were
significant predictors of
worse HRQoL.

− ESS was not
objectively
assessed
− Many
comorbidities
were not
considered
− Patients able to
come to and
suitable for
examination and
interview were
included
− Dementia
patients were
excluded

Factor 2 (PD symptoms at
night): 2.56 ± 2.78
Factor 3 (disturbed sleep):
6.96 ± 3.59

− No control
population was
recruited
− Apathy and
depression were
not evaluated
− Certain
confounding
factors were not
completely
excluded
− Cross-sectional
study; cannot
determine
causality
− Lack of objective
measures

SD = standard deviation, HRQoL = Health-related quality of life, UPDRS = Unified Parkinson's Disease Rating Scale, PDQ = Parkinson’s Disease
Questionnaire, MOS = Medical Outcomes Study, SF-36 = Short Form-36, PCS = Physical Composite Score, MCS = Mental Composite Score, ESS = Epworth
Sleepiness Scale, IQR = interquartile range, RBDSQ = REM sleep behavior disorder sleep questionnaire, EQ-5D = EuroQol-5 Dimension, PDSS = Parkinson’s
disease sleep scale, SCOPA = Scales for Outcomes in Parkinson’s disease, PSQI = Pittsburgh Sleep Quality Index, PIGD = postural instability gait difficulty, TD
= tremor-dominant, p-PIGD = predominantly postural instability gait difficulty, p-TD = predominantly tremor-dominant, NMSQuest = Non-Motor Symptoms
Questionnaire, NHP = Nottingham health profile, PD = Parkinson’s disease, RCSQ = Richards-Campbell Sleep Questionnaire, WHOQOL-OLD = World Health
Organization Quality of Life Assessment for Older Adults, PWS = Psychological Wellbeing Scale, YOPD = young-onset Parkinson’s disease, MOPD = middleonset Parkinson’s disease, LOPD = late-onset Parkinson’s disease, NS = nighttime sleep problems, DS = daytime sleepiness, ADL = Activities of Daily Life,
MMSE = Mini Mental State Examination, EDS = Excessive daytime sleepiness, WHO5 = World Health Organization Well-being Questionnaire
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Factor 1 (motor symptoms
at night): 2.50 ± 2.55

Table 2.6: Sleep, health-related quality of life among caregivers of persons with Parkinson’s disease

Publication Year,

HRQoL and caregiver
burden measurement tool
and score

Mean ± SD

Mean ± SD

Country
Bartolomei et al.43
2018
Italy

Patients

Caregivers

Patients

PDSS: 36.7
± 21.9

MOS-SS
index II:
20.1 ± 18.1

PDQ-39:
29.8 ± 20.2

ESS: 4.8 ±
3.3

Cupidi et al.25
2012
Italy

NR

PSQI: 6.25
± 3.9

Caregiver
HRQoL:

SF-36 MHS:
75.0 ± 17.7

CBI: 9.0 ±
12.5

NR

Study limitations

Caregivers

SF-36 PHS:
85.9 ± 18.5

PDSS was a
significant
predictor of
caregiver
sleep
quality
(MOS-SS
index II).

HRQoL and caregiver
burden results

MQoL: 7.3 ±
1.4

Patient sleep (PDSS) was
associated with lower
caregiver physical and
mental health scores,
respectively. Patient HRQoL
(PDQ-39) was not
significantly associated with
caregiver HRQoL.

The relationship between
PDSS and caregiver burden
was not significant. Patient
HRQoL was significantly
associated with greater
caregiver burden.
Poor sleepers had
significantly lower QoL
compared to good sleepers.
The relationship between
sleep and psychological

− Small sample
size (N = 75)
− Fewer patients
with higher
levels of
disease
severity
− Cannot
establish
causality
without
longitudinal
studies

− Lack of
objective
sleep quality
measures
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Author,

Sleep measurement tool
& score

2012
Turkey

PDSS:
satisfied
with sleep
(N = 40,
80%)

ESS:
pathological
sleep (N =
9, 18%)

ESS; no
caregivers
experienced
pathological
sleepiness

Turkish
version of
WHOQOLBREF

symptoms domain of QoL
was mediated by depression.

Turkish
version of
WHOQOLBREF

No significant relationship
was found between patient
and caregiver demographic
characteristics and caregiver
WHOQOL-BREF domain
scores.

ZBI: 27.6 ±
15.1
Significant positive
correlation was observed
between patients’ daytime
sleepiness level (ESS) and
caregiver burden.

− Patients’ sleep
was not
collected
− Relatively
small sample
size (N = 50)
− Use of scales
for
psychological
assessment
instead of
psychologicalstatus
examination
measure
− Patients had
difficulty
understanding
WHOQOLBREF
questions

SD = standard deviation, HRQoL = Health-related quality of life, PDSS = Parkinson’s disease sleep scale, ESS = Epworth Sleepiness Scale, MOS-SS = Medical
Outcomes Study – Sleep Scale, PDQ = Parkinson’s Disease Questionnaire, SF-36 = Short Form-36, PHS = Physical health scale, MHS = Mental health scale,
CBI = Caregiver Burden Inventory, SCOPA = Scales for Outcomes in Parkinson’s disease, NR = not reported, EQ-5D = EuroQol-5 Dimension, ZCBI = Zarit
Caregiver Burden Inventory, PSQI = Pittsburgh Sleep Quality Index, MQoL = McGill Quality of Life Questionnaire, WHOQOL-BREF = World Health
Organization Quality of Life Assessment-Bref, SDI = Sleep Disturbances Inventory, MPDSS = Modified Parkinson’s Disease Sleep Scale
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Ozdilek et al.46

CBI: 13.4 ±
13.4

Table 2.7: Quality appraisal of included patient studies

Andreadou
et al.48
Avidan et
al.14
Baig et
al.39
Fan et al.53
Gallagher
et al.17
GómezEsteban et
al.13
Havlikova
et al.18
Herman et
al.58

Year

Q1*

Q2

Q3

Q4

Q5

Q6

Q7

Q8

Q9

2011

Y

Y

Y

Y

Y

Y

Y

Y

Include

2012

Y

Y

Y

Y

Y

Y

Y

Y

Include

2015

Y

Y

Y

Y

Y

Y

Y

Y

Include

2016

Y

Y

Y

Y

Y

Y

Y

Y

Include

2010

Y

Y

Y

Y

Y

Y

Y

Y

Include

2010

Y

Y

Y

Y

Y

Y

Y

Y

Include

2011

Y

Y

Y

Y

Y

Y

Y

Y

Include

2015

Y

Y

Y

Y

Y

Y

Y

Y

Include

1999

Y

Y

Y

Y

Y

Y

Y

Y

Include

2019

Y

Y

Y

Y

Y

Y

Y

Y

Include

2014

Y

Y

Y

Y

Y

Y

Y

Y

Include

Lee et al.56

2018

Y

Y

Y

Y

Y

Y

Y

Y

Include

Lerman et
al.57

2019

Y

Y

Y

Y

Y

Y

Y

Y

Include

Karlsen et
al.77
Kuhlman
et al.16
Lee et al.49

Q10
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Author

Included
based on
correlation
results
presented

2010

Y

Y

Y

Y

Y

Y

Y

Y

Include

2010

Y

Y

Y

Y

N

N

Y

Y

Include

2017

Y

Y

Y

Y

Y

Y

Y

Y

Include

2019

Y

Y

Y

Y

Y

Y

Y

Y

Include

Naismith
et al.55

Nicoletti et
al.59

Palmeri et
al.66
Pandey et
al.60

Park et
al.44
Qin et al.41
Semiz et
al.50
Skorvanek
et al.47
Sun et al.68
Tibar et
al.54

2016

Y

Y

Y

Y

N

N

Y

Y

Include

2018

Y

Y

Y

Y

Y

Y

Y

Y

Include

2009

Y

Y

Y

Y

Y

Y

Y

Y

Include

2007

Y

Y

Y

Y

Y

Y

Y

Y

Include

2015

Y

Y

Y

Y

Y

Y

Y

Y

Include

2018

Y

Y

Y

Y

Y

Y

Y

Y

Include

2018

Y

Y

Y

Y

Y

Y

Y

Y

Include

Included
based on
correlation
results
presented
Included
based on
correlation
results
presented
Included
based on
correlation
results
presented

Included
based on
correlation
results
presented
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Margis et
al.52

2019

Y

Y

Y

Y

Y

Y

Y

Y

Include

2008

Y

Y

Y

Y

Y

Y

Y

Y

Include

2014

Y

Y

Y

Y

Y

Y

Y

Y

Include

2019

Y

Y

Y

Y

Y

Y

Y

Y

Include

2017

Y

Y

Y

Y

Y

Y

Y

Y

Include

2019

Y

Y

Y

Y

Y

Y

Y

Y

Include

2015

Y

Y

Y

Y

Y

Y

Y

Y

Include

Y = Yes, N = No
*
Q1-Q10 correspond to items in the quality appraisal form presented in Table 2.2.
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Vila Cha
et al.51
Visser et
al.40
Walton et
al.67
Xiang et
al.20
Ylikoski et
al.42
Yoo et
al.45
Yu et al.15

Table 2.8: Quality appraisal of included caregiver studies
Author

Year

Q1

Q2

Q3

Q4

Q5

Q6

Q7

Q8

Q9

Bartolomei et al.43

2018

Y

Y

Y

Y

Y

Y

Y

Y

Include

2012

Y

Y

Y

Y

Y

Y

Y

Y

Include

2012

Y

Y

Y

Y

Y

Y

Y

Y

Include

Cupidi et al.

25

Ozdilek et al.46

Q10

63

Y = Yes
*
Q1-Q10 correspond to items in the quality appraisal form presented in Table 2.2.
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CHAPTER 3: PSYCHOMETRIC EVALUATION OF THE PROMIS® GLOBAL
HEALTH QUESTIONNAIRE IN PERSONS WITH PARKINSON’S DISEASE AND
THEIR CAREGIVERS
Introduction
Parkinson’s disease (PD) is a commonly occurring nervous system disorder that causes
tremors, muscle stiffness, and loss of gait and balance – referred to as motor symptoms. It is
accompanied by several non-motor symptoms including orthostatic hypotension, mood
disorders, sleep disorders, urinary problems, difficulty swallowing, skin issues, among others.
Consequently, health-related quality of life (HRQoL) is severely affected among persons with
Parkinson’s (PWP). PWP tend to face a similar overall economic burden when compared to
certain other chronic conditions, but their HRQoL seems to be worse in comparison.1,2
Several patient-reported outcome (PRO) measures have been used to measure HRQoL in
PD to evaluate the impact of disease from the patient’s perspective. The most commonly used
disease-specific measures include the Parkinson’s Disease Questionnaire-39 (PDQ-39) and its
short form version, the PDQ-8, both of which were developed in the 1990’s.3,4 The PDQ-39
contains 39 items measuring 8 domains: mobility, activities of daily living, emotional wellbeing, stigma, social support, cognitions, communication, and bodily discomfort. The domain
scores can be combined into a single PD Summary Index (PDSI), and both the domain and the
summary index are reported on a scale of 0 (perfect health) to 100 (worst health).4,5 The PDQ-39
exhibited good internal consistency (except for the social support domain), test-retest reliability,
and construct validity against the Medical Outcomes Study 36-item Short Form Health Survey
(SF-36).3 The most commonly used generic HRQoL measures in PD include the following: The
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Nottingham Health Profile (NHP),6 the Sickness Impact Profile (SIP),7 the EuroQol (EQ-5D),8
and the SF-36,9 all of which have been designated as “recommended” scales in a critique by the
Movement Disorder Society (MDS).10 The critique concluded that these scales exhibited
satisfactory psychometric properties in PD, except for the NHP which showed floor and ceiling
effects compared to the PDQ-39.10,11
All the above-mentioned scales and their scoring algorithms were developed using
Classical Test Theory (CTT) methods. However, Item-Response Theory (IRT) has gained
increasing attention as a modern alternative scaling procedure to CTT.12 While there are
commonalities between the two approaches (the assumption of scale unidimensionality, for
example), there are also various distinctions in their fundamental philosophies regarding scale
properties. Two important differences between them include: (1) IRT’s focus on individual item
properties vs. CTT’s focus on the scale as a whole, and (2) Scale scoring in CTT is done
assuming that all individual items in the questionnaire are equally important in measuring the
latent variable. However, in IRT, items have varying levels of difficulty, and therefore, it is
possible to identify items that can differentiate between specific levels of the construct being
measured.12 Scales developed using IRT methods consider the probability a respondent selects a
particular response category, given their level of the underlying latent train that the scale is
measuring rather than the sample in which the trait is being measured and hence, perform better
when ceiling and floor effects are expected.12,13
The Patient-Reported Outcomes Measurement Information System (PROMIS®) was an
NIH-funded initiative established in 2004, which incorporated the use of IRT methods to develop
and validate PROs used in clinical practice and research.14,15 The PROMIS inventory comprises
of over 300 measures that evaluate individuals with chronic conditions and the general
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population on domains and subdomains that fall under the World Health Organization’s physical,
mental and social framework for health.16 These questionnaires were developed over a few years
and began by conducting extensive literature search of existing PROs to create item banks across
constructs identified within domains. This was followed by qualitative item-review procedures to
assess items for content validity and deletion of items which were confusing, redundant or poorly
written. Finally, psychometric testing was done using CTT and IRT procedures to create final
sets of item banks.17 Moreover, since the PROMIS inventory contains generic questionnaires,
they can be used across all samples (e.g., patients, healthy persons, patients at all disease severity
levels ) allowing us to compare diverse samples on the same scale.
Some PROMIS measures have been previously tested in subgroups of PD,18,19 however,
there are no published studies evaluating the performance of the PROMIS® Global Health
measure in PWP. This measure assesses an individual’s physical, mental and social health.17,20
The PROMIS Global Health questionnaire consists of 10-items covering the following domains:
physical health, mental health, pain, fatigue, social health, and overall health. The PROMIS
Global Health item set includes a self-rated health item (global01) which has been shown to tap
in to both physical health and mental health but reflects physical health more than mental
health.21 It also includes a single item for overall quality of life (global02). The remaining items
are ratings of physical health (global03), mental health (global04), social health (global05 and
global09R), physical function (global06), pain (global07R), fatigue (global08R), and emotional
distress (global10R). All items other than pain (global07R) are measured on a 5-category
response scales where higher scores on responses indicate better health. Pain (global07) is
measured on a scale of 0 – 10, where 0 = no pain and 10 = worst pain imaginable. A T-score
metric is calculated for the scores which can be compared to the standard US population with a
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mean of 50 and standard deviation of 10. A higher score on an instrument indicates that the
respondent has “more” of the concept being measured. Summary score for global physical health
(GPH) is calculated by averaging scores across 4 items: global03 (physical health), global06
(physical function), global07R (pain) and global08R (fatigue).20 Similarly, global mental health
(GMH) is calculated by averaging scores across the following 4 items: global02 (quality of life),
global04 (mental health), global05 (satisfaction with discretionary social activities) and
global10R (emotional problems).20 Items with the suffix “R” indicate reverse-coded items in the
questionnaire. The current study aimed to evaluate psychometric properties of the PROMIS®
Global Health measure and also evaluate differential item functioning of the measure’s items in
PWP.
Methods
Study sample
The current cross-sectional study was conducted by means of a web-based, selfadministered survey, distributed to a national convenience sample of PWP and caregivers from
Rare Patient Voice (RPV), LLC, Dynata, LLC, and Parkinson and Movement Disorder (PMD)
Alliance. RPV and Dynata are market research vendor companies which maintain and provide
researchers with panels of patients and caregivers across several medical conditions for
conducting surveys and interviews. PMD Alliance is a national independent, not-for-profit
patient advocacy group. All study participants were 50 years of age or older. The study protocol
was deemed exempt by the University of Mississippi Institutional Review Board.
Study methodology
A survey with questions on respondent demographics and other required study measures
was developed using Qualtrics online survey software (Qualtrics Inc., Provo, UT). The survey
instrument is provided in the Appendix. A cover letter explaining the objective and scope of the
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study was sent to the participants in an email. The email also contained information pertaining to
eligibility criteria, nature of questions being asked, risks and benefits from the study, assurances
on data security and confidentiality, participation incentive, contact information of the principal
investigator and a URL link to the survey for PWP. Upon receiving adequate sample size, the
survey was closed. The de-identified dataset containing the study measures was used for
analysis. Each study participant was provided an incentive for completing the survey.
Study measures
The following measures were collected from PWP (See Appendix 4 for survey
instrument):
PROMIS Global Health (PROMIS-GH): The PROMIS GPH and GMH summary scores were
calculated from items mentioned earlier, using a web-based application the HealthMeasures
Scoring ServiceSM (HM-SS).22 This application was developed by the PROMIS Group and is
available free of cost for researchers. The other two items (global01 – general health and
global09 – social roles) were scored individually.
Patient Global Impression of Severity (PGI-S): PGI-S is a single self-reported measure that
measures a patient’s self-rated symptom severity. In this study, the question was worded as
“Please circle the response below that best describes the severity of your motor symptoms over
the past week”, with the following response categories: 1 = normal, 2 = borderline, 3 = mild, 4 =
moderate, 5 = severe, 6 = extreme. A similarly worded question was added to elicit non-motor
(NM) symptom severity as well. The response categories were created based on a 2015 study
which compared various commonly used disease severity measures in PD.23
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Other measures: Information was also collected on the following characteristics: (1) age, (2)
race/ethnicity, (3) sex, (4) education status, (5) employment status, (6) symptom severity (in
terms of PGI-S as mentioned above), (7) current anti-parkinsonian treatment use. Additionally,
because data were collected near the beginning of the Coronavirus Disease 2019 (COVID-19)
pandemic, questions regarding COVID-19 were asked to understand anxiety surrounding the
pandemic and the impact of the pandemic on HRQoL.
Statistical Analysis
Sample description
Descriptive statistics were calculated in the form of frequencies and percentages for
categorical variables and means and standard deviations for continuous variables.
Item-level analysis
Item-level descriptive statistics were calculated in terms of means, and standard
deviations (SD). Response patterns, including patterns in missing data, were examined and
presented in terms of frequencies. This step is fundamental in ensuring there are no systematic
patterns in responses and warrants further investigation, if any. For example, more prevalent
missing data might be seen towards the end of the survey, which may signal response burden.
Floor and ceiling effects were also examined at the item- and summary score-levels.
Internal consistency reliability
Ordinal alpha based on polychoric correlations was used to examine internal consistency
and a minimum of 0.70 was considered as the threshold for reliable group-level measurement.24
Factorial validity
Categorical item, confirmatory factor analysis (CFA) based on polychoric correlations
was conducted using the weighted least squares mean- and variance-adjusted estimator
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(WLSMV) to evaluate the factorial validity of GPH and GMH (i.e., the existence of an
underlying 2-factor measurement model). Goodness-of-fit was assessed using comparative fit
index (CFI), Tucker-Lewis Index (TLI), and the root mean square error of approximation
(RMSEA). The following thresholds were used for models with a good fit: CFI ≥ 0.95, TLI ≥
0.95, and RMSEA ≤ 0.06, respectively.25
Differential item functioning
When a questionnaire is used in a diverse sample, the assumption is that all items in the
questionnaire perform similarly across the subgroups in that sample and that the differences
observed in their scores is due to a difference in the constructs being measured between the
groups.26 However, sometimes this assumption is violated, which gives rise to differential item
functioning (DIF).12,26 In the current study, we tested for age- and sex-DIF in the PROMIS
Global Health measure. We used the two-factor measurement model that was estimated in the
previously conducted categorical item CFA for the following steps.
Multiple-groups CFA: This step involved testing for measurement invariance and the presence of
DIF using a multi-group CFA for categorical outcomes. First, a model where all the parameters
are allowed to freely vary was estimated. The following stepwise approach suggested by Brown
(2015)27 was used for the next steps:
i.

testing the CFA model for each group separately (for example, between males vs.
females for sex-based invariance testing).

ii.

establishing a baseline multiple-groups model wherein the factor loadings and thresholds
are freely estimated in all groups. This model is also referred to as the equal form model.

iii.

conducting a model in which all factor loadings and thresholds are constrained to equality
across all groups (measurement invariance model). A significant degradation in model fit
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was considered to indicate DIF. In case of model fit degradation, modification indices
(MI) and standardized expected parameter changes (EPC) were examined to identify
indicators that were noninvariant.
iv.

if noninvariance was encountered in the previous step, a partial invariance model was
estimated in which factor loadings and thresholds for all indicators are held equal across
the groups, except for the indicator that was nonivariant. Again, model fit statistics, MI
and EPC were used to identify items exhibiting further DIF.
These steps were repeated for the age variable. This approach has been used previously with

other PROMIS short forms.28–30
Known-groups validity
Known-groups validity was assessed in PWP with respect to self-reported motor and NM
symptom severity levels. Symptom severity as measured by PGI-S were collapsed in to 3 groups
where response levels 1, 2, and 3 were classified as mild cases, level 4 as moderate, and levels 5
and 6 as severe. This approach was modeled after a previous study that compared severity scales
in PD.23 One-way ANOVA was used to compare GPH and GMH scores obtained from the
PROMIS Global Health measure across PWP with different severity levels. Pairwise
comparisons were assessed using Tukey’s Honestly Significant Difference (HSD) test.
All CFA models were estimated using Mplus version 8.5 (Muthén & Muthén, Los
Angeles, CA) and all other analyses were conducted in SAS version 9.4 (SAS Institute, Cary,
NC).
Results
Sample characteristics
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A total of 261 PWP responded to the survey. The majority of respondents were male
(59%), 66 years or older (63%), White (77%), had less than a bachelor’s degree (57%), were
retired (53%), and had public insurance (66%) (Table 3.1). Sixty-two percent of participants
were recruited through online panels (RPV and Dynata) and the remaining 38% were recruited
from a patient advocacy group (PMD Alliance).
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Table 3.1: Socio-demographic characteristics of persons with Parkinson’s disease included
in the study
Characteristic

Sex
Age group
(in years)
Race

Highest education
level

Employment status

Health insurance

Category
Female
Male
Other/prefer not to answer
50-65
66 or older
White
Other
GED or High school diploma
Associate degree
Bachelor's degree
Master's degree
Terminal degree
No degree
Retired
Unable to work
Employed for wages
Self-employed
Out of work for 1 year or more
Out of work for less than 1 year due to
COVID-19, also known as Coronavirus
or SARS-CoV-2
Out of work for less than 1 year due to
other reason(s)
Public insurance (e.g. Medicare,
Medicaid, VA)
Private insurance
Other
Uninsured

Patients (N = 261)
N (%)
105 (40.2)
154 (59.0)
2 (0.8)
96 (36.8)
165 (63.2)
201 (77.0)
60 (23.0)
84 (32.2)
47 (18.0)
65 (24.9)
29 (11.1)
18 (6.9)
18 (6.9)
138 (52.9)
38 (14.6)
32 (12.3)
5 (1.9)
23 (8.8)
14 (5.4)
5 (1.9)
172 (65.9)
82 (31.4)
5 (1.9)
2 (0.8)

Clinical characteristics of the PWP sample
Among participants, 43% reported a moderate level of symptom severity for both motor
and NM symptoms (Table 3.2). About 35% participants reported mild/borderline/normal motor
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symptoms, while 22% reported severe/extreme symptoms. For NMS, 40% reported
mild/borderline/normal symptoms and 17% reported sever/extreme symptoms. Respondents also
reported having at least one chronic condition, other than PD. The most commonly reported
chronic conditions included arthritis (28%), mood disorders (27%), heart disease (20%) and
diabetes (17%).

Table 3.2: Clinical characteristics of persons with Parkinson’s disease included in the study
Characteristic

Category

Normal
Borderline
Mild
Self-reported motor
*
symptom severity
Moderate
Severe
Extreme
Normal
Borderline
Mild
Self-reported non-motor
*
symptom severity
Moderate
Severe
Extreme
Number of chronic conditions (Mean ± SD, Median, Range)

Patients (N = 261)
N (%)
20 (7.7)
22 (8.4)
63 (24.1)
86 (33.0)
55 (21.1)
15 (5.8)
31 (11.9)
11 (4.2)
72 (27.6)
110 (42.2)
31 (11.9)
6 (2.3)
1.5 ± 1.9, 1, 1-13

*

Patient Global Impression of Severity (PGI-S) was used to measure motor and non-motor symptom severity.
SD = standard deviation

Item-level analysis of PROMIS Global Health questionnaire
Table 3.3 below shows item-level characteristics of the PROMIS Global Health
questionnaire in the current study sample. The entire sample responded to most items, except for
1 missing response each for global04 (mental health) and global08R (fatigue) items. The highest
proportion of respondents with the minimum possible score was observed for the global03
(physical health, 12%). The highest proportion of respondents who had the maximum possible
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score was seen with the item global06 (physical function, 16%). These results indicate that the
floor and ceiling effects are close to the suggested threshold of 15%.31 The lowest mean score
was observed for the item global03 (2.5 ± 0.9) and the highest mean score was observed for
GLOBAL06 (3.1 ± 1.1).
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Table 3.3: PROMIS Global Health-10 item-level analysis
N

Missing

Floor
(%)

Ceiling
(%)

Mean

SD

global01*

261

0

11.1

3.5

2.7

1.0

In general, would you say your health is

global02*

261

0

7.7

5.4

2.9

1.0

In general, would you say your quality of life is:

global03*

261

0

11.9

2.3

2.5

0.9

In general, how would you rate your physical health?

global04*

260

1

7.7

8.5

3.0

1.1

global05*

261

0

7.3

6.1

2.9

1.0

global09R*

261

0

10.0

4.6

2.8

1.0

global06†

261

0

6.1

16.1

3.1

1.1

global10R§

261

0

8.1

7.7

3.0

1.0

global08R‡

260

1

5.4

3.9

2.9

0.9

global07R⁑

261

0

1.9

6.5

3.0

0.9

Item text

In general, how would you rate your mental health,
including your mood and your ability to think?
In general, how would you rate your satisfaction with
your social activities and relationships?
In general, please rate how well you carry out your
usual social activities and roles. (This includes
activities at home, at work and in your community, and
responsibilities as a parent, child, spouse, employee,
friend, etc.)
To what extent are you able to carry out your everyday
physical activities such as walking, climbing stairs,
carrying groceries, or moving a chair?
How often have you been bothered by emotional
problems such as feeling anxious, depressed or
irritable?
How would you rate your fatigue on
average?
How would you rate your pain on average?

PROMIS = Patient Reported Outcomes Measurement Information System, GPH = Global Physical Health, GMH = Global Mental Health, SD = Standard
deviation
*
Response categories are: Excellent = 5, Very good, Good, Fair, Poor = 1.
†
Response categories are: Completely = 5, Mostly, Moderately, A little, Not at all = 1.
§
Response categories are: Never = 5, Rarely, Sometimes, Often, Always = 1.
‡
Response categories are: None = 5, Mild, Moderate, Severe, Very severe = 1.
⁑
Responses are on a scale of 0 (no pain) to 10 (worst pain imaginable), recoded as follows: 0 = 5; 1-3 = 4; 4-6 = 3; 7-9 = 2; 10 = 1.
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PROMIS item
identifier

PROMIS Global Physical and Mental health summary scores and internal consistency
reliability
The mean GPH summary score in the study sample was 43.1 ± 8.5 and the mean GMH
summary score was 38.7 ± 8.0 (Table 3.4). The GPH and GMH scales had an internal
consistency reliability (ordinal alpha coefficient) of 0.772 and 0.843, respectively.

Table 3.4: Physical and mental health summary scores and reliability analysis for PROMIS
Global Health among persons with Parkinson’s disease
Component

Mean (SD)

Floor (%)

Ceiling (%)

Ordinal alpha

No. of items

PROMIS GPH

43.1 (8.5)

0

0

0.772

4

PROMIS GMH

38.7 (8.0)

1.5

0

0.843

4

PROMIS = Patient Reported Outcomes Measurement Information System, GPH = Global Physical Health, GMH =
Global Mental Health, SD = standard deviation
For GPH, the highest possible score is 67.7 and the lowest possible score is 16.2.
For GMH, the highest possible score is 67.6 and the lowest possible score is 21.2.

Factorial validity
Figures 3.1, 3.2. and 3.3 represent the models that were estimated to test the factorial
validity of PROMIS Global Health among PWP. The factor loadings and goodness-of-fit indices
for each of the tested models are presented in Table 3.5. The two-factor model where global03
(physical health), global06 (physical function), global07R (pain) and global08R (fatigue) load on
GPH, and global02 (quality of life), global04 (mental health), global05 (satisfaction with
discretionary social activities) and global10R (emotional problems) load on GMH is presented in
model 1 (Figure 3.1). This model did not include specifications for correlated errors between any
items. Model 1 had a poor fit (Chi-square [df] = 222.815 [19]; CFI = 0.922; TLI = 0.885;
RMSEA [90% CI] = 0.203 [0.179, 0.227]). Based on MI and standardized EPC values, a residual
correlation was added between global07R (pain) and global08R (fatigue) to this model, which is
represented here as model 2 (Figure 3.2). This model also had somewhat poor fit (Chi-square [df]
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= 157.353 [18]; CFI = 0.947; TLI = 0.917; RMSEA [90% CI] = 0.172 [0.148, 0.197]). Again,
modification indices and standardized EPC values were examined to identify local areas of
strain. Based on these values, a method effect between reverse-coded items (global07R [pain] –
global10R [emotional problems] and global08R [fatigue] – global10R [emotional problems])
was identified. Therefore, residual correlations were specified for these terms in addition to
correlation between pain and fatigue to form model 3 (Figure 3.3). These specifications
significantly improved model fit (Chi-square [df] = 44.230 [16]; CFI = 0.989; TLI = 0.981;
RMSEA [90% CI] = 0.082 [0.054, 0.112]).
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Figure 3.1: Model 1 – Two-factor model for PROMIS Global Health without any
correlated errors between items

gmh = global mental health, gph = global physical health, g_emo = emotional problems (global10R), g_sat =
satisfaction with discretionary social activities (global05), g_mh = mental health (global04), g_qol = quality of life
(global02), g_pain = pain (global07R), g_fati = fatigue (global08R), g_pa = physical function (global06), g_ph =
physical health (global03)
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Figure 3.2: Model 2 – Two-factor model for PROMIS Global Health with correlated errors
for global07R (pain) and global08R (fatigue)

gmh = global mental health, gph = global physical health, g_emo = emotional problems (global10R), g_sat =
satisfaction with discretionary social activities (global05), g_mh = mental health (global04), g_qol = quality of life
(global02), g_pain = pain (global07R), g_fati = fatigue (global08R), g_pa = physical function (global06), g_ph =
physical health (global03)
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Figure 3.3: Model 3 – Two-factor model for PROMIS Global Health with correlated errors
for all reverse-coded items (global07R: pain, global08R: fatigue and global10R: emotional
problems)

gmh = global mental health, gph = global physical health, g_emo = emotional problems (global10R), g_sat =
satisfaction with discretionary social activities (global05), g_mh = mental health (global04), g_qol = quality of life
(global02), g_pain = pain (global07R), g_fati = fatigue (global08R), g_pa = physical function (global06), g_ph =
physical health (global03)
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Table 3.5: Standardized factor loadings and summary of model fit indices from
confirmatory factor analysis of the two-factor structures of PROMIS Global Health
Items

Estimate* (SE)
Model 1

Model 2

Model 3

Global03

0.832 (0.025)

0.832 (0.025)

0.860 (0.025)

Global06

0.778 (0.033)

0.778 (0.033)

0.797 (0.033)

Global08R

0.666 (0.035)

0.615 (0.039)

0.577 (0.042)

Global07R

0.471 (0.041)

0.402 (0.043)

0.348 (0.045)

Global02

0.881 (0.021)

0.879 (0.021)

0.900 (0.021)

Global04

0.806 (0.026)

0.809 (0.026)

0.826 (0.027)

Global05

0.732 (0.031)

0.734 (0.031)

0.747 (0.032)

Global10R

0.653 (0.034)

0.650 (0.034)

0.580 (0.038)

0.934 (0.023)

0.962 (0.025)

0.921 (0.024)

-

0.387 (0.045)

0.426 (0.042)

-

-

0.0.373 (0.045)

-

-

0.332 (0.050)

222.815 (19),
<0.0001
0.922

157.353 (18),
<0.0001
0.947

0.885

0.917

0.981

0.203 (0.179, 0.227)

0.172 (0.148, 0.197)

0.082 (0.054, 0.112)

GPH Component

GMH Component

Latent factor correlation
GPH with GMH
Correlated residuals
Global07R with
Global08R
Global07R with
Global10R
Global08R with
Global10R
Model fit
Chi-square (df), pvalue
CFI
TLI
RMSEA (90% CI)

44.230 (16), 0.0002
0.989

SE = standard error, df = degrees of freedom, CFI = Comparative Fit Index, TLI = Tucker-Lewis Index, RMSEA =
Root Mean Square Error of Approximation, CI = Confidence Interval
Items are as follows: G
Model 1: Two-factor structure where GLOBAL03, GLOBAL06, GLOBAL07R and GLOBAL08R load on global
physical health and GLOBAL02, GLOBAL04, GLOBAL05 and GLOBAL10R load on global mental health, with
no correlated errors.
Model 2: Two-factor structure as in Model 1 above with correlated errors for GLOBAL08R and GLOBAL07R.
Model 3: Two-factor structure as in Model 1 above with correlated errors among all reverse-coded items:
GLOBAL08R, GLOBAL07R and GLOBAL10R.
*
All factor loadings were significant at α = 0.05.
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Differential item functioning by sex and age group
Using the two-factor structure of PROMIS Global Health with the best fit specified in
model 3, the possibility of DIF was explored using multi-group CFA based on sex and age group
(Table 3.6). First, DIF based on sex (males vs. females) was examined. The baseline or equal
form model, where factor loadings and thresholds were freely estimated in both groups, fit the
data well (Chi-square [df] = 60.576 [32]; CFI = 0.989; TLI = 0.981; RMSEA [90% CI] = 0.083
[0.050, 0.115]). The measurement invariance model, where both factor loadings and thresholds
were constrained to be equal across males and females, showed that the constraint did not
degrade model fit relative to the baseline model (Chi-square difference [df] = 39.415 [28], pvalue = 0.0745). Therefore, it was concluded that there was no indication of DIF between males
and females.
Next, DIF based on age group (50-65 vs. 66+ years) was examined using model 3. The
baseline model showed good fit for the data (Chi-square [df] = 72.712 [32]; CFI = 0.986; TLI =
0.975; RMSEA [90% CI] = 0.099 [0.069, 0.129]). The measurement invariance model showed a
significant increase in chi-square (Chi-square difference [df] = 52.866 [28], p-value = 0.0030).
MI and EPC indicated that the item global08R (fatigue) was noninvariant between the two age
groups. Therefore, a partial invariance model was estimated where factor loadings and thresholds
for this item were freely estimated between the two groups, whereas all other items were
constrained to be equal. This model did not result in a significant increase in chi-square relative
to the baseline model (Chi-square difference [df] = 37.327 [27], p-value = 0.0891), providing no
evidence for further DIF in the model.
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Table 3.6: Differential item functioning (DIF) by sex and age group in PROMIS Global
Health based on Model 3
Model

Chi-square
(df)

p-value

CFI

TLI

RMSEA
(90% CI)

Chi-square
difference (df)
p-value

Sex-based DIF
Free
parameter

60.576 (32)

0.0017

0.989

0.981

Fixed

91.180 (60)

0.0058

0.988

0.989

72.712 (32)

0.0001

0.986

0.975

113.343
(60)

<0.0001

0.981

0.982

96.265 (59)

0.0016

0.987

0.987

0.083 (0.050,
0.115)
0.063 (0.035,
0.089)

39.415 (28)
0.0745

Age-based DIF
Free
parameter
Fixed
Global08R

0.099 (0.069,
0.129)
0.083 (0.059,
0.106)
0.070 (0.043,
0.094)

52.866 (28)
0.0030
37.327 (27)
0.0891

GLOBAL08R item: “How would you rate your fatigue on average?” with response categories: None (5), Mild,
Moderate, Severe, Very severe (1).
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Known-groups validity
Known-groups validity was examined based on the ability of GPH and GMH to
discriminate between PWP with motor and NM symptoms at mild, moderate and severe levels
using one-way ANOVA (Table 3.7 and 3.8). Pairwise comparisons between the different
symptom severity groups were assessed using Tukey’s Honestly Significant Difference (HSD)
test.
Motor symptom severity groups: The mean GPH (43.7 vs. 37.3 vs. 32.9; p<0.0001) and GMH
(46.9 vs. 41.5 vs. 39.2; p<0.0001) summary scores were significantly different between the three
symptom severity groups (Table 3.7). There was a reduction in GPH scores with increasing
severity level. Specifically, PWP with mild symptoms had significantly higher GPH score than
the moderate group (43.7 vs. 37.3) and severe group (43.7 vs. 32.9). PWP with moderate severity
had significantly higher GPH than the severe group (37.3 vs. 32.9). As for GMH summary
scores, the mild symptoms group had higher GMH score than the moderate (46.9 vs. 41.5) and
the severe groups (46.9 vs. 39.3), but there was no evidence that the moderate and severe groups
were different with respect to GMH scores (41.5 vs. 39.3, p = 0.2092).
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Table 3.7: Known-groups validity for PROMIS Global Health components among PWP
based on motor symptom severity
Motor symptom severity

Component

Mild
(N = 105)

Moderate
(N = 86)

Severe
(N = 70)

p-value

Mean (SD)
GPH

43.7 (7.7)*¥

37.3 (5.5)*†

32.9 (6.2)†¥

<0.0001

GMH

46.9 (8.6)§‡

41.5 (7.3)§

39.3 (7.5)‡

<0.0001

GPH = Global Physical Health, GMH = Global Mental Health, SD = standard deviation
*
p<0.0001 for difference in mean GPH summary scores between the “Mild” symptom group compared to
“Moderate” based on Tukey’s Honestly Significant Difference (HSD) test.
†
p<0.0001 for difference in mean GPH summary scores between the “Moderate” symptom group compared to
“Severe” based on Tukey’s HSD test.
¥
p<0.0001 for difference in mean GPH summary scores between the “Mild” symptom group compared to “Severe”
based on Tukey’s HSD test.
§
p<0.0001 for difference in mean GMH summary scores between the “Mild” symptom group compared to
“Moderate” based on Tukey’s HSD test.
‡
p<0.0001 for difference in mean GMH summary scores between the “Mild” symptom group compared to “Severe”
based on Tukey’s HSD test.
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Non-motor symptom severity groups: The mean GPH (42.9 vs. 37.0 vs. 30.8; p<0.0001) and
GMH (46.9 vs. 41.4 vs. 36.4; p<0.0001) summary scores were significantly different between
the three symptom severity groups (Table 3.8). There was a reduction in GPH and GMH scores
with increasing severity level. Specifically, PWP with mild symptoms had significantly higher
GPH score than the moderate group (42.9 vs. 37.0) and severe group (42.9 vs. 30.8). PWP with
moderate severity had significantly higher GPH than the severe group (37.0 vs. 30.8). As for
GMH summary scores, the mild symptoms group had higher GMH score than the moderate (46.9
vs. 41.4) and the severe groups (46.9 vs. 36.4). Additionally, the moderate group had
significantly higher GMH score compared to the severe group (41.4 vs. 36.4).

Table 3.8: Known-groups validity for PROMIS Global Health components among PWP
based on non-motor symptom severity

Component

Mild
(N = 114)

Moderate
(N = 110)

Severe
(N = 37)

p-value

Mean (SD)
GPH

42.9 (7.4)*¥

37.0 (6.1)*†

30.8 (6.6)†¥

<0.0001

GMH

46.9 (8.6)§‡

41.4 (6.1)§⸸

36.4 (8.9)⸸‡

<0.0001

GPH = Global Physical Health, GMH = Global Mental Health, SD = standard deviation
*
p<0.0001 for significant difference in mean GPH summary scores between the “Mild” symptom group compared to
“Moderate” based on Tukey’s Honestly Significant Difference (HSD) test.
†
p<0.0001 for significant difference in mean GPH summary scores between the “Moderate” symptom group
compared to “Severe” based on Tukey’s HSD test.
¥
p<0.0001 for significant difference in mean GPH summary scores between the “Mild” symptom group compared to
“Severe” based on Tukey’s HSD test.
§
p<0.0001 for significant difference in mean GMH summary scores between the “Mild” symptom group compared
to “Moderate” based on Tukey’s HSD test.
⸸
p = 0.0024 for significant difference in mean GMH summary scores between the “Moderate” symptom group
compared to “Severe” based on Tukey’s HSD test.
‡
p<0.0001 for significant difference in mean GMH summary scores between the “Mild” symptom group compared
to “Severe” based on Tukey’s HSD test.
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Impact of COVID-19 on health-related quality of life
Results from the COVID-19 responses are presented in Table 3.9. A total of 259 survey
participants responded to these questions. The mean anxiety score (on a scale of 1-10 with 1
being low and 10 being high) among the participants was 5.8 ± 2.6. When asked about how their
quality of life has been impacted as a result of the COVID-19 pandemic, 69% of the participants
responded “worsened” and 32% responded “remained the same”, whereas less than 2%
responded “improved”. When asked about their agreement with the statement “The COVID-19
pandemic has had a significant impact on my quality of life”, more than half of the participants
answered “somewhat agree” (48%) or “strongly agree” (24%).

Table 3.9: Impact of COVID-19 on quality of life in PWP
COVID-19 related items
COVID-19 related anxiety
(Mean ± SD, Median, Range)
Change in quality of life as a
result of COVID-19

Category
On a scale of 1-10
(1 = Low, 10 = High)

Patients (N = 259)*
5.8 ± 2.6, 6, 1-10

Worsened

173 (66.8)

Remained the same

82 (31.7)

Improved

4 (1.5)

Level of agreement with statement related to the impact of COVID-19

The COVID-19 pandemic has
had a significant impact on
my quality of life

Strongly disagree

23 (8.9)

Somewhat disagree

18 (7.0)

Neither disagree nor agree

33 (12.7)

Somewhat agree

124 (47.9)

Strongly agree

61 (23.6)

PWP = Persons with Parkinson’s, COVID-19 = Coronavirus Disease 2019
*259 of 261 total respondents answered the COVID-19 related questions.
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Discussion
The current study aimed to assess the measurement properties of the PROMIS Global
Health questionnaire in a sample of PWP. For this purpose, we analyzed primary data collected
from PWP through panels and a patient advocacy group. We found that the mean GPH (43.1)
and GMH (38.7) summary scores were lower than the standard US population, indicating worse
physical and mental health in this sample. This difference is to be expected in a chronic,
progressive neurodegenerative disease such as PD and is consistent with previous evidence.32
We evaluated item-level descriptive statistics as well as floor and ceiling effects and
found that the instrument performed well on all these aspects. Floor and ceiling effects were
minimal for each item and were non-existent at the summary score level, which highlights the
advantage of instruments developed in the IRT framework compared to CTT.12,13 Studies have
shown that legacy instruments such as NHP, SF-36 etc. and also some disease-specific scales
might exhibit floor and ceiling effects in PD.33–35 PROMIS Global Health instrument could be
used as an alternate generic instrument in case of severe floor and ceiling effects.
Additionally, factorial validity of PROMIS Global Health was tested by examining the
proposed two-factor structure,20 which showed poor fit. This finding was consistent with two
other studies which evaluated the scale’s factorial validity in samples of stroke patients by
Katzan et al.36 and pregnant and postpartum women by Slavin et al.37 To address this issue,
Slavin et al. revised items loading onto the GPH and GMH components and proposed the use of
alternative versions. However in our sample, upon further investigation, we identified method
effects with regards to reverse coded items (global07R – pain, global08R – fatigue and
global10R – emotional problems) leading to model misfit. Consequently, specification of
correlated residuals among these items to the model significantly improved fit. These three items
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were reverse coded with the intention to score all items in PROMIS Global Health in such a way
so that higher scores represent better functioning.38 However, researchers have questioned the
effectiveness of including such items and have argued that these items might in fact lead to
confusion among participants.39 In order to overcome such issues, some researchers have
suggested that users could take advantage of the greater flexibility in terms of item customization
allowed by PROMIS item banks and critically consider the inclusion of reverse-scored items
based on the need for the particular project.29
The current study conducted exploratory DIF analyses and the results showed that there
was no DIF across males and females. However, we did observe DIF based on age. The results
indicate that for the same level of underlying latent trait of physical health, younger and older
PWP scored differently on the global08R (fatigue) item and therefore, the observed scores may
not be directly comparable between these two groups. To our knowledge, this is the first study to
examine age based DIF in PD. However, studies which have evaluated PROMIS Global Health
in other populations have not found evidence suggesting age-based DIF.40,41 Further evaluations
of DIF in other PD and disease samples are needed to understand if this finding was specific to
the current study sample.
With regards to known-groups validity, the study findings show that PROMIS Global
Health demonstrates the ability to differentiate across PWP at various levels of self-reported
motor and NM symptom severity. Both GPH and GMH scores were found to be significantly
different across the various levels of NM severity and direction of the effect, i.e. decreasing GPH
and GMH scores with increasing symptom severity, are consistent with our expectation. While
GPH scores were significantly different across all pairwise comparisons of the three motor
symptom severity levels, GMH was only found to be significantly different when comparing the
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mild motor symptom group to each of the higher motor symptom groups. This finding suggests
that GMH summary score may not be able to discriminate between the moderate and the severe
motor symptom groups.
There are some limitations in our study. First, data collection was conducted during the
COVID-19 pandemic which may have affected PWP’s responses to the survey questions,
especially HRQoL. Additionally, participant responses to the survey questions may be prone to
recall bias and social desirability bias. As this was a survey of PWP, we did not have access to
clinician-reported disease severity measure (such as the Hoeh & Yahr stages). Future studies
could consider evaluating the performance of the PROMIS Global Health measure against
disease-specific instruments in PD.
Conclusion
This study provides evidence about the satisfactory psychometric properties of the
PROMIS Global Health instrument in an online sample of PWP. It was found to have adequate
internal consistency reliability, and factorial and known-groups validity among PWP in research
settings. The scale showed no DIF based on sex. The presence of DIF was seen with respect to
the fatigue item across age groups. Additional studies are needed to ascertain these findings in
other samples and to understand the performance of the instrument in comparison to legacy
instruments specific to PD.
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CHAPTER 4: DYADIC RELATIONSHIP BETWEEN SLEEP AND HEALTHRELATED QUALITY OF LIFE IN PERSONS WITH PARKINSON’S DISEASE AND
THEIR CAREGIVERS – AN ACTOR-PARTNER INTERDEPENDENCE MODEL
APPROACH
Introduction
Parkinson’s disease (PD) is the second most common disorder of the central nervous
system which predominantly affects dopaminergic neurons in a specific area of the brain called
substantia nigra. The disease characterized by motor symptoms such as tremors, rigidity,
slowness of movement etc. and non-motor symptoms (NMS) such as sleep disorders, psychosis,
mood disorders, orthostatic hypotension etc. NMS have consistently been shown to have a
greater impact on health-related quality of life than motor symptoms among persons with PD
(PWP).1,2 The most frequently occurring NMS among PWP include different types of sleep
disorders such as rapid eye movement (REM) sleep behavior disorder (RBD), insomnia,
nocturia, restless legs syndrome (RLS)/periodic limb movement disorder (PLMD), sleep
disordered breathing (SDB), excessive daytime sleepiness (EDS), and circadian rhythm
disorders.3
Impact of sleep disorders on PWP and caregivers in PD
The impact of sleep disorders in PD is multidimensional. Sleep disorders have been
shown as an important predictor of poor health-related quality of life (HRQoL) in PWP.4–7
Moreover, previous studies have suggested that sleep disorders are also highly correlated with
other NMS that contribute to poor HRQoL such as depression,8–11 pain,11 fatigue,12,13 and
cognitive impairment.14,15 Enhanced sleep quality, on the other hand, has been shown to improve
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working memory in PWP, which is an indicator of improved higher cognitive functioning
involving planning, problem solving, delayed goal execution and overall fluid intelligence.16
Further, sleep-related disorders in PWP are associated with diminished sleep quality
among caregivers, the prevalence of which has been estimated as 20-60% across samples.10,17–19
Several factors may contribute to the manifestation of sleep disorders in the caregiver. Smith et
al. hypothesized that caregivers’ own distress from caregiving during the day could be one of the
predictors.17 Another study involving in-depth interviews with caregivers found that nocturnal
caregiving responsibilities such as attending to nocturnal physical needs of a PWP, anticipation
of nocturnal care needs, monitoring a PWP during sleep, and a PWP’s sleep disturbances may
help explain sleep abnormalities in caregivers and may contribute to caregivers’ own sleep
disturbances.20 This negative influence of sleep disorders in PWP on caregivers’ HRQoL has
also been shown in quantitative studies.5,8,21,22A better understanding of this relationship can help
develop interventions that can reduce the burden of sleep disorders and improve HRQoL in PWP
and caregivers.
Interdependence of sleep in PWP and caregivers
Several studies have evaluated the impact of sleep on PWP and caregiver HRQoL.
However, there are certain limitations to the methods used in these studies. The relationship
between PWP and their caregivers involves mutuality where either of them could influence the
other’s behaviors. From the stresses of nocturnal caregiving needs,10,17–19 it is evident that sleep
is one such interrelated concept for the PWP-caregiver dyad and therefore, any methods
evaluating its effects on PWP’s HRQoL or their caregivers’ HRQoL should also take this
interdependence in to consideration.
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Most studies assess the impact of PWP’s clinical characteristics on their own HRQoL or
caregivers’ HRQoL independently. Specifically, in the context of sleep disorders, the
nonindependence of PWP’s and their caregivers’ sleep quality is often ignored or one of the
measurements is not collected or not used during analysis. This may give rise to biased
parameter estimates and biased variances and degrees of freedom in statistical tests, which leads
to biased statistical significance tests and standardized effect measures, loss in precision of
estimates, and loss in power.23 These biased estimates lead to inaccuracies in estimating the
actual disease burden.
Moreover, one of the key applications of estimates of the association between sleep and
HRQoL is to quantify the effect of PWP’s illness (i.e., patients’ sleep disorders) on caregivers’
HRQoL, otherwise known as spillover effects. The National Institute of Health and Care
Excellence (NICE) and the second panel of cost-effectiveness in health and medicine highlight
the importance of incorporating spillover effects in pharmacoeconomic evaluations.24–27
Unbiased estimates are needed to avoid misinterpretation of benefits of health interventions.
Therefore, there is a need to identify an appropriate statistical analytic technique which accounts
for the dyadic nature of the patient-caregiver relationship when assessing the effect of sleep on
HRQoL of PWP and caregivers.
The current study utilizes a dyadic analytic model to assess the relationship between
sleep and HRQoL in PD, an association that has traditionally been interpreted as an independent
phenomenon in PWP and caregivers. However, there is a growing acceptance among researchers
that sleep is influenced by social factors, such as physical comfort and emotional safety, which
are regulated by close human relationships.28,29 Therefore, there is a need to identify models that
appropriately assess and enhance our understanding of sleep’s impact on HRQoL in PWP106

caregiver dyads in PD. Hence, the specific aim of the study is to assess the dyadic relationship
between sleep and HRQoL in PWP and their caregivers using the Actor-Partner Interdependence
Model (APIM). The APIM was developed and used extensively in psychological research to
address data that involve mutual influence of thoughts, emotions and behaviors between two
persons involved in close relationships.23,30 The APIM has been used to understand relational
phenomena in other disease areas (to test the dyadic impact of depression and anxiety on HRQoL
in HIV/AIDS,31 for example) and to certain relationships in PD (to examine the dyadic
relationship between benefit finding and relationship quality,32 for example). The current study
aimed to extend its application to study the dyadic relationship between sleep and HRQoL in
PWP and caregivers.
Methods
Study sample
A national convenience sample of 108 PWP-caregiver dyads was obtained from two
market research firms – Rare Patient Voice (RPV), LLC, and Dynata, LLC. All study
participants were 18 years of age or older. The unit of analysis for the current study is a dyad
containing a PWP and the PWP’s caregiver. Therefore, PWP were linked to their family
caregivers by RPV and Dynata with the use of a unique linking variable to create PWP-caregiver
dyads. Since the proposed model contains variables that are distinguishable between PWP and
their caregivers, survey responses were collected individually from them. Dyad members were
eligible to participate in the study if the caregiver was the primary informal caregiver of the
PWP, the PWP was at least 50 years old, and both members resided in the same household. The
study protocol was deemed exempt by the University of Mississippi Institutional Review Board.
Study methodology
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The current study used a cross-sectional study involving data collected through a webbased survey. A survey containing questions regarding participant demographics and other study
measures was created using Qualtrics online survey software (Qualtrics Inc., Provo, UT). A
cover letter explaining the purpose of the study, eligibility criteria, nature of questions being
asked, risks and benefits from the study, details on data security and confidentiality, participation
incentive, contact information of the principal investigator and the study URL link were sent in
an email to PWP and caregivers. Upon receiving sufficient number of complete, usable
responses the survey was closed, and the research team had access to a de-identified dataset
containing the study measures with linked responses from PWP and their caregivers, which was
used for analysis. Each study participant was provided an incentive for completing the survey.
Study measures
The main variables of interest in this study, HRQoL and sleep, were measured using the
Patient-Reported Outcomes Measurement Information System (PROMISTM) questionnaires.
PROMIS was an NIH-funded initiative established in 2004, which aimed to develop and validate
patient-reported outcomes (PROs) for use in clinical practice and research.33 The PROMIS
research network focused on improving PROs using state-of-the-art psychometric methods (i.e.,
Item-Response Theory (IRT)).34 The PROMIS inventory includes over 300 measures that
evaluate and monitor physical, mental and social health in individuals with chronic conditions
and the general population. All PROMIS scales are measured on a T-score metric which allows
for comparison to the standard US population with a mean of 50 and SD of 10. A higher score
indicates that the individual has “more” of the concept being measured by the scale. Moreover,
since the PROMIS inventory contains generic questionnaires, they can be used across all samples
(patients, healthy persons, patients at all disease severity levels etc.) allowing us to compare
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these diverse samples on the same scale. For this study, the HealthMeasures Scoring ServiceSM
(HM-SS), a software application developed by the PROMIS Group was used to calculate the
summary scores as described below.35
PROMISTM – Global Health: The 10-item questionnaire covering physical health, mental health,
pain, fatigue, social health and overall health was used to measure HRQoL in patients and
caregivers. Two summary scores were calculated using 8 of the 10-items. The Global physical
health (GPH) summary score is obtained by averaging across physical health (global03),
physical function (global06), pain (global07), and fatigue (global08).34 The Global mental health
(GMH) summary score is obtained by averaging scores across overall quality of life (global02),
mental health (global04), social health (global05), and emotional distress (global10).36
PROMISTM – Sleep disturbance (SD): The 8-item short form version of this questionnaire was
used to measure nocturnal sleep disturbances in patients and caregivers.
PROMISTM – Sleep-related impairment (SRI): The 8-item short form version of this
questionnaire was used to measure daytime sleepiness in patients and caregivers.
Patient Global Impression of Severity (PGI-S): PGI-S is a single self-reported measure that
measures a patient’s self-rated disease severity. In this study, the question was worded as “Please
circle the response below that best describes the severity of your Parkinson’s disease symptoms
over the past week”, with the following response categories: 1 = normal, 2 = borderline, 3 =
mild, 4 = moderate, 5 = severe, 6 = extreme. The response categories were created based on a
2015 study which compared various commonly used disease severity measures in PD.37
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Other measures: Information was also collected on the following characteristics: (1) age, (2)
race/ethnicity, (3) sex, (4) education status, (5) occupational status, (6) relationship to care
recipient/caregiver, (7) duration of disease, (8) disease severity (in terms of PGI-S as mentioned
above), (9) current anti-parkinsonian treatment use, (10) current sleep diagnosis, (11) current
sleep-related treatment use, (12) number of caregiving hours per week (only to the caregiver).
COVID-related questions: Finally, since data collection took place during the Coronavirus
Disease 2019 (COVID-19) pandemic, we also included questions pertaining to anxiety related to
the pandemic and its impact on sleep and HRQoL for each participant. See Appendices 4 and 5
for survey instruments for PWP and caregivers, respectively.
Statistical analysis
Sample description
Descriptive statistics were calculated in the form of frequencies and percentages for
categorical variables and means and standard deviations for the continuous variables. Pearson’s
product-moment correlation coefficients were calculated to assess correlations between the
PROMIS measures for PWP and caregivers.
Actor-Partner Interdependence Model (APIM)
The APIM23 is used to estimate dyadic data where the effects of interest are of mixed
variables, i.e. variables that vary both between dyads and within dyads. The model allows for
estimation of actor effects (the impact of an individual’s independent variable on their own
dependent variable) and partner effects (the impact of an individual’s independent variable on
the other dyad member’s dependent variable). The subsequent improvement in assessing disease
burden and pharmacoeconomic models could potentially translate into better policies and
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healthcare interventions for PWP and caregivers. In this study, PROMIS-SD and PROMIS-SRI
were considered as independent variables and PROMIS GMH and GPH summary scores were
considered as dependent variables.
Figure 4.1 represents a conceptual model of the APIM for two dyad members 1 and 2. In
this model, X1 and X2 represent the independent or predictor variables of dyad members 1 and 2,
respectively. Similarly, Y1 and Y2 represent the dependent or outcome variables. The impact of
X1 on Y1 represents actor effects for dyad member 1 (a1). Similarly, the effect of X2 on Y2
represents actor effects for dyad member 2 (a2). On the other hand, the effect of X2 on Y1 (p12)
and the effect of X1 on Y2 (p21) represent their respective partner effects. In addition, the APIM
allows for two correlations: (1) correlation between the independent variables (X1 and X2,
represented by the curved line on the left), referred to as the compositional effect, where in
relationships where members of a dyad were similar to each other even before pairing, (2)
correlation between the dependent variables (Y1 and Y2 represented by the correlation between
E1 and E2 on the right), which represents the nonindependence not explained by the model.
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Figure 4.1: A conceptual model of the Actor-Partner Interdependence Model

Note: X1 and X2 represent the predictor variables for dyad members 1 and 2, respectively. Y 1 and Y2 represent the
dependent variables for dyad members 1 and 2 respectively. The curved double-headed arrows on the left represent
the covariances between the independent variables, and the curved double-headed arrow on the right the correlation
between the two error terms. The solid lines represent the actor effects (a1 and a2) and the dashed lines represent the
partner effects (p12 and p21).

Structural equation modeling (SEM) solution with distinguishable dyads was used to
assess the models.23,38 Within the APIM, the following four patterns have been suggested,23
where a represents actor effects, p represents partner effects and k represents the ratio parameter.
k parameter is calculated as the ratio of partner effects to actor effects for a dyad member.
Dyadic patterns were assessed based on an approach suggested by Fitzpatrick et al.39
i.

actor-oriented (a ≠ 0, p = 0, k = 0): in this model, the person’s outcomes are a function of
their own characteristics and the partner’s characteristics have no impact.

ii.

partner-oriented (a = 0, p ≠ 0, k = 0): in this model, the person’s outcomes are purely a
function of their partner’s characteristics and their own characteristics have no impact.
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iii.

couple-oriented (a = p, k = 1): in this model, the actor and partner effects are equal, i.e. a
person’s outcomes are as influenced by their own characteristics as much as their
partner’s characteristics.

iv.

social comparison (a + p = 0, k = -1): in this model, the actor and partner effects are equal
in magnitude but opposite in direction. Consider the example where the actor effect is
positive and partner effect is negative. In this case, the actor effect is a positive predictor
of the outcome, whereas the partner effect is a negative predictor of the outcome.
Two parameters k1 for PWP and k2 for caregivers were estimated in the saturated model

and bootstrapped 95% confidence intervals were obtained to identify possible dyadic patterns.
Upon identifying a possible pattern, a model where these parameters were constrained to the
hypothesized values as mentioned above was estimated to see if the model fit worsened. Model
fit was assessed using the chi-square statistic, comparative fit index (CFI) and root mean square
error of approximation (RMSEA). For CFI, values greater than 0.95 were considered for good
fit. A 90% confidence interval for RMSEA with lower and upper bounds between 0 and 0.08,
respectively, were considered to indicate good model fit. These bounds are based on the cutoffs
of 0.01, 0.05 and 0.08 suggested for excellent, good and mediocre fit by MacCallum, Browne
and Sugawara.40 Data management and descriptive statistics for the sample were conducted in
SAS 9.4 (SAS Institute, Cary, NC). All SEM-based analyses were conducted using Mplus
version 8.5 (Muthén & Muthén, Los Angeles, CA).
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Results
Socio-demographic and clinical characteristics of the PWP-caregiver dyads
A total of 108 PWP-caregiver dyads completed the online survey. Sociodemographic
characteristics of the dyad members are provided in Table 4.1. Compared to their caregivers, a
greater proportion of PWP were male (67% vs. 39%), had less than a bachelor’s degree (53% vs.
42%), were retired (60% vs. 31%) and were enrolled in public health insurance programs (80%
vs. 49%). Race was evenly distributed in both groups. The majority of the dyad members
reported a household income level of $50,000 or more. Most caregivers were spouses (59%) of
the PWP and were full-time caregivers (47%). The median number of chronic conditions in PWP
and their caregivers was 2 and 1, respectively.
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Table 4.1: Socio-demographic characteristics of persons with Parkinson’s disease and their
caregivers included in the study
Characteristic

Category

Female
Male
Sex
Other/prefer not to answer
50-65
66-75
Age group
(in years)
76-85
86 or older
Age (in years) (Mean ± SD, Range)
White
Race
Other
GED or High school
diploma
Associate degree
Highest
Bachelor's degree
education level
Master's degree
Terminal degree
No degree
Retired
Unable to work
Employed for wages
Self-employed
Out of work for 1 year or
more
Employment
Out of work for less than
status
1 year due to COVID-19,
also known as
Coronavirus or SARSCoV-2
Out of work for less than
1 year due to other
reason(s)
Public insurance (e.g.
Medicare, Medicaid, VA)
Health insurance Private insurance
Other
Uninsured
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Patients (N = 108)
N (%)

Caregivers (N = 108)
N (%)

35 (32.4)
72 (66.7)
1 (0.9)
35 (32.4)
52 (48.2)
17 (15.7)
4 (3.7)
94 (87.0)
14 (13.0)

66 (61.1)
42 (38.9)
-

56.0 ± 15.0, 28-89
94 (87.0)
14 (13.0)

39 (36.1)

20 (18.7)

12 (11.1)
35 (32.4)
8 (7.4)
8 (7.4)
6 (5.6)
65 (60.2)
19 (17.6)
9 (8.3)
2 (1.9)

23 (21.5)
40 (37.4)
16 (15.0)
6 (5.6)
2 (1.9)
33 (30.6)
7 (6.5)
43 (39.8)
5 (4.6)

5 (4.6)

6 (5.6)

2 (1.9)

7 (6.5)

4 (3.7)

1 (0.9)

86 (79.6)

52 (48.6)

21 (19.4)
1 (0.9)

48 (44.9)
3 (2.8)
4 (3.7)

-

$15,000 to less than
$25,000
$25,000 to less than
Household
$35,000
income
35,000 to less than
(N = 107)
$50,000
$50,000 or more
Spouse or significant
other
Caregiver’s
Son/daughter
relationship to
PWP
Other relative
Other non-relative
Caregiving time 20 or fewer
per week
21-39
(in hours)
40 or more
Number of care recipients (including primary
PWP) (Mean ± SD, Median, Range)
Number of chronic conditions (Mean ± SD,
Median, Range)

11 (10.3)
11 (10.3)
18 (16.8)
67 (62.6)
64 (59.3)
19 (17.6)
21 (19.4)
4 (3.7)

PWP = Persons with Parkinson’s
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-

31 (28.7)
26 (24.1)
51 (47.2)

-

1.6 ± 1.1, 1, 0-6

1.8 ± 1.7, 2, 0-8

1.4 ± 1.4, 1, 0-8

Clinical characteristics of PWP cohort
Forty-three percent of PWP reported moderate severity for both motor and NM
symptoms (Table 4.2). About 35% reported normal-to-mild motor symptoms and 41% reported
normal-to-mild NM symptoms. A lower proportion of PWP (22% for motor, 17% for NM)
reported having severe or extreme symptoms. Within treatments, use of oral formulations of
carbidopa-levodopa (44.4% for Sinemet CR, 17% for Rytary) was most commonly reported
among PWP. About 23% of the PWP also reported use of melatonin supplements. Among
caregivers, 31% reported having been diagnosed by a healthcare professional with a sleep
disorder and 43% reported use of a medication to manage their sleep problems (Table 4.3).

117

Table 4.2: Clinical characteristics of PWP included in the study
Characteristic

Self-reported motor
symptom severity*

Self-reported non-motor
symptom severity*

Anti-parkinsonian/sleep
treatment use

Category
Normal
Borderline
Mild
Moderate
Severe
Extreme
Normal
Borderline
Mild
Moderate
Severe
Extreme
Sinemet CR (carbidopa-levodopa
controlled release tablets)
Melatonin supplements
Klonopin (clonazepam)
Rytary (carbidopa-levodopa
extended-release capsules)
Seroquel (quetiapine)
Mirapex (pramipexole)
Deep-brain stimulation
Ambien (zolpidem)
Duopa (carbidopa-levodopa enteral
suspension)
Lunesta (eszopiclone)
Nuplazid (pimavanserin)
Requip (ropinirole)
Desyrel (trazodone)
Silenor (doxepin)
Other+

Patients (N = 108)
N (%)
5 (4.6)
8 (7.4)
25 (23.2)
46 (42.6)
20 (18.5)
4 (3.7)
8 (7.4)
6 (5.6)
30 (27.8)
46 (42.6)
15 (13.9)
3 (2.8)
48 (44.4)
25 (23.2)
18 (16.7)
18 (16.7)
17 (15.7)
16 (14.8)
12 (11.1)
8 (7.4)
8 (7.4)
8 (7.4)
8 (7.4)
7 (6.5)
6 (5.6)
5 (4.6)
29 (26.87)

PWP = Persons with Parkinson’s
*
Patient Global Impression of Severity (PGI-S) was used to measure motor and non-motor symptom severity.
+
‘Other’ category under anti-parkinsonian/sleep treatment use included Neupro (rotigotine transdermal system),
Sonata (zaleplon), Provigil (modafinil), Nuvigil (armodafinil), Ritalin (methylphenidate) and Clozaril (clozapine).
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Table 4.3: Clinical characteristics of caregivers of PWP included in the study
Characteristic
Sleep diagnosis

Current sleep medication use

Response
Yes
No
Uncertain
Yes
No
Uncertain

Caregivers (N= 108)
N (%)
33 (30.6)
68 (63.0)
7 (6.5)
46 (42.6)
60 (55.6)
2 (1.9)

PWP = Persons with Parkinson’s

Sleep and health-related quality of life among PWP and their caregivers
The average scores for PROMIS-SD, PROMIS-SRI, PROMIS GMH and GPH measures
are provided in Table 4.4. The average GPH and GMH summary scores for PWP were 46.4
(±8.6) and 40.6 (±8.4), respectively. For caregivers, the average GPH summary score was 46.2
(±8.8) and the average GMH summary score was 36.9 (±7.0). On PROMIS-SD, PWP had a
mean score of 56.3 (±9.4) and caregivers had a mean score of 55.9 (±9.9). Whereas on PROMISSRI, PWP reported an average score of 59.5 (±10.6) and their caregivers reported 56.0 (±11.7).
PWP and caregiver responses to questions related to the impact of COVID-19 are
presented in Table 4.5. On a scale of 1 (low) – 10 (high), PWP reported a mean anxiety score of
5.8 (±3.0) and caregivers reported a mean anxiety score of 5.9 (±2.8). When asked about change
in sleep quality as a result of COVID-19, most PWP (68%) and caregivers (69%) reported that it
remained the same. With regards to quality of life, most PWP (65%) and caregivers (62%)
reported that it had worsened as a result of COVID-19. About 37% of PWP and 34% of
caregivers agreed that COVID-19 had a significant impact on their sleep quality. Whereas, 67%
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of PWP and 62% of caregivers agreed that COVID-19 had a significant impact on their quality
of life.
Table 4.4: PROMIS global mental and physical summary scores, sleep disturbance and
sleep-related impairment in PWP-caregiver dyads
Patients (N = 108)
(Mean ± SD)

Caregivers (N = 108)
(Mean ± SD)

40.6 ± 8.4

46.4 ± 8.6

36.9 ± 7.0

46.2 ± 8.8

Sleep Disturbance (PROMIS-SD)

56.3 ± 9.4

55.9 ± 9.9

Sleep-Related Impairment (PROMIS-SRI)

59.5 ± 10.6

56.0 ± 11.7

Measure
PROMIS Global Mental Health Summary
Score
PROMIS Global Physical Health Summary
Score

PWP = Persons with Parkinson’s
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Table 4.5: Impact of COVID-19 on sleep and quality of life in PWP-caregiver dyads
COVID-19 related
items
COVID-19 related
anxiety
(Mean ± SD, Range)
Change in sleep
quality as a result of
COVID-19
Change in quality of
life as a result of
COVID-19

Category

Patients (N = 107)*
N (%)

Caregivers (N = 108)
N (%)

On a scale of 1-10
(1 = Low, 10 = High)

5.8 ± 3.0, 1-10

5.9 ± 2.8, 1-10

Worsened

33 (30.8)

33 (30.6)

Remained the same

73 (68.2)

74 (68.5)

Improved

1 (0.9)

1 (0.9)

Worsened

69 (64.5)

67 (62.0)

Remained the same

38 (35.5)

39 (36.1)

-

2 (1.9)

Improved

Level of agreement with statements related to the impact of COVID-19

The COVID-19
pandemic has had a
significant impact on
the quality of my
sleep

The COVID-19
pandemic has had a
significant impact on
my quality of life

Strongly disagree

34 (31.8)

36 (33.3)

Somewhat disagree

19 (17.8)

18 (16.7)

Neither disagree nor
agree

14 (13.1)

17 (15.7)

Somewhat agree

26 (24.3)

22 (20.4)

Strongly agree

14 (13.1)

15 (13.9)

Strongly disagree

13 (12.2)

9 (8.3)

Somewhat disagree

8 (7.5)

13 (12.0)

Neither disagree nor
agree

14 (13.1)

18 (16.7)

Somewhat agree

45 (42.1)

36 (33.3)

Strongly agree

27 (25.2)

32 (29.6)

PWP = Persons with Parkinson’s, COVID-19 = Coronavirus Disease 2019
*107 PWP responded to the COVID-19 related questions.
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The Actor-Partner Interdependence model for sleep and HRQoL measures
Because the PROMIS-SD and PROMIS-SRI were strongly correlated within persons in
our sample (r = 0.822, p < 0.001 for PWP and r = 0.803, p < 0.001 for caregivers) (Table 4.6),
separate API models were conducted with PROMIS-SD and PROMIS-SRI as the independent
variables to avoid potential for multicollinearity. Consequently, four separate models were
conducted where two models estimated the dyadic impact of sleep disturbance on GPH and
GMH, respectively, and two models estimated the impact of sleep-related impairment on GPH
and GMH, respectively.
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Table 4.6: Correlations of PROMIS global mental and physical health summary scores, sleep disturbance and sleep-related
impairment in PWP-caregiver dyads
1

2

3

4

5

6

PWP mental health
summary score

1.000

2

PWP physical health
summary score

0.690*

1.000

3

PWP sleep
disturbance

-0.482*

-0.539*

1.000

4

PWP sleep-related
impairment

-0.471*

-0.581*

0.822*

1.000

0.348*

0.297**

-0.321*

-0.265***

1.000

0.182

0.296**

-0.279**

-0.278**

0.638*

1.000

Caregiver mental
5 health summary
score
Caregiver physical
6 health summary
score
7

Caregiver sleep
disturbance

-0.341*

-0.456*

0.556*

0.460*

-0.521*

-0.559*

1.000

8

Caregiver sleeprelated impairment

-0.323*

-0.427*

0.442*

0.413*

-0.499*

-0.656*

0.803*

*p ≤ 0.001, **p ≤ 0.05, ***p ≤ 0.01

8
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1

7

1.000

Impact of sleep disturbance on physical and mental health
APIM results for model 1 and 2 are presented in Table 4.7. In model 1 where PROMIS
GPH summary score was regressed on PROMIS-SD (Figure 4.2), two significant actor effects
were identified: PWP’s sleep disturbance on their own physical health (unstandardized estimate
= -0.309, 95% CI: [-0.446, -0.168]) and caregiver’s sleep disturbance on their own physical health
(unstandardized estimate = -0.517, 95% CI: [-0.680, -0.371]). Additionally, a statistically
significant partner effect of caregiver’s sleep disturbance on PWP’s physical health
(unstandardized estimate = -0.160, 95% CI: [-0.304, -0.031]) was identified. Subsequently, a model
with couple-oriented (k1 = 1) and actor-oriented dyadic patterns (k2 = 0) was estimated for PWP
and caregivers, respectively, which had a reasonably good fit.
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Figure 4.2: Actor-Partner Interdependence Model showing actor and partner effects for
the impact of sleep disturbance on PROMIS Global Physical Health summary score

Note: Actor and partner effects of PROMIS-sleep disturbance on PROMIS global physical health summary score. In
the graphical representation above, the rectangles represent the independent and dependent variables; the two circles
on the right present the latent error terms; and the arrows describe the actor and partner effects. The curved doubleheaded arrows on the left represent the covariances between the independent variables, and the curved doubleheaded arrow on the right the correlation between the two error terms. The solid lines represent the actor effects and
the dashed lines represent the partner effects. Standardized coefficients and standard errors are reported in
parentheses. The model did not include control variables.
*
p < 0.05, **p < 0.001

In model 2 where PROMIS GMH summary score was regressed on PROMIS-SD (Figure
4.3), two significant actor effects were identified: PWP’s sleep disturbance on their own mental
health (unstandardized estimate = -0.380, 95% CI: [-0.562, -0.178]) and caregiver’s sleep
disturbance on their own physical health (unstandardized estimate = -0.432, 95% CI: [-0.586, 0.281]) (Table 4.7). No significant partner effects were identified. Subsequently, a model with

actor-oriented dyadic patterns (k1 = 0, k2 = 0) was estimated for PWP and caregivers, respectively,
which showed good fit.
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Figure 4.3: Actor-Partner Interdependence Model showing actor and partner effects for
the impact of sleep disturbance on PROMIS Global Mental Health

Note: Actor and partner effects of PROMIS-sleep disturbance on PROMIS global mental health summary score. In
the graphical representation above, the rectangles represent the independent and dependent variables; the two circles
on the right present the latent error terms; and the arrows describe the actor and partner effects. The curved doubleheaded arrows on the left represent the covariances between the independent variables, and the curved doubleheaded arrow on the right the correlation between the two error terms. The solid lines represent the actor effects and
the dashed lines represent the partner effects. Standardized coefficients and standard errors are reported in
parentheses. The model did not include control variables.
*
p < 0.05, **p < 0.001
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Table 4.7: Actor-Partner Interdependence Model parameter estimates for sleep
disturbance and physical and mental health
Model 1: Physical health
(PROMIS GPH summary score)

Model 2: Mental health
(PROMIS GMH summary score)

Unstandardized estimate
(95% CI)

p-value

Unstandardized estimate
(95% CI)

p-value

a1

-0.309 (-0.446, -0.168)

<0.001

-0.380 (-0.562, -0.178)

<0.001

a2

-0.517 (-0.680, -0.371)

<0.001

-0.432 (-0.586, -0.281)

<0.001

p12

-0.160 (-0.304, -0.031)

0.023

-0.089 (-0.253, 0.054)

0.246

p21

0.043 (-0.129, 0.201)

0.607

-0.042 (-0.200, 0.106)

0.584

Actor effects

Partner effects

Dyadic patterns
Couple-oriented for PWP and actororiented for caregiver (k1 = 1, k2 = 0)

Actor-oriented for PWP and caregivers
(k1 = 0, k2 = 0)

k1

0.517 (0.086, 1.668)

0.234 (-0.117, 1.110)

k2

-0.084 (-0.362, 0.283)

0.097 (-0.215, 0.566)

2

2

1.808

1.421

0.000 (0.000, 0.185)

0.000 (0.000, 0.172)

1.000

1.000

Hypothesis

Model fit
df

Chi-square
RMSEA
(90% CI)
CFI

a1 = actor effect (PWP), a2 = actor effect (caregiver), p12 = impact of caregiver’s sleep disturbance on PWP’s
physical/mental health (partner effect), p21 = impact of PWP’s sleep disturbance on their caregiver’s physical/mental
health (partner effect), k1 and k2 = k (ratio) parameters to estimate dyadic patterns for PWP and caregiver,
respectively, df = degrees of freedom, RMSEA = root mean square error of approximation, CI = confidence interval,
CFI = comparative fit index
The model did not include control variables.
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Impact of sleep-related impairment on physical and mental health
APIM results for model 3 and 4 are presented in Table 4.8. Model 3, where PROMIS
GPH summary score was regressed on PROMIS-SRI (Figure 4.4), identified two significant
actor effects: PWP’s sleep-related impairment on their own physical health (unstandardized
estimate = -0.323, 95% CI: [-0.461, -0.170]) and caregiver’s sleep-related impairment on their own
physical health (unstandardized estimate = -0.488, 95% CI: [-0.616, -0.353]). Additionally, a
statistically significant partner effect of caregiver’s sleep-related impairment on PWP’s physical
health (unstandardized estimate = -0.135, 95% CI: [-0.256, -0.013]) was identified. Subsequently, a
model with couple-oriented (k1 = 1) and actor-oriented dyadic patterns (k2 = 0) was estimated for
PWP and caregivers, respectively, which did not worsen model fit.
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Figure 4.4: Actor-Partner Interdependence Model showing actor and partner effects for
the impact of sleep-related impairment on PROMIS Global Physical Health summary
score

Note: Actor and partner effects of PROMIS sleep-related impairment on PROMIS global physical health summary
score. In the graphical representation above, the rectangles represent the independent and dependent variables; the
two circles on the right present the latent error terms; and the arrows describe the actor and partner effects. The
curved double-headed arrows on the left represent the covariances between the independent variables, and the
curved double-headed arrow on the right the correlation between the two error terms. The solid lines represent the
actor effects and the dashed lines represent the partner effects. Standardized coefficients and standard errors are
reported in parentheses. The model did not include control variables.
*
p < 0.05, **p < 0.001

In model 4 where PROMIS GMH summary score was regressed on PROMIS-SRI
(Figure 4.5), two significant actor effects were identified: PWP’s sleep-related impairment on
their own mental health (unstandardized estimate = -0.322, 95% CI: [-0.485, -0.104]) and
caregiver’s sleep disturbance on their own physical health (unstandardized estimate = -0.346, 95%
CI: [-0.469, -0.216]) (Table 4.8). No significant partner effects were identified. Subsequently, a

model with actor-oriented dyadic patterns (k1 = 0, k2 = 0) was estimated for PWP and caregivers,
respectively, which showed reasonable fit.
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Figure 4.5: Actor-Partner Interdependence Model showing actor and partner effects for
the impact of sleep-related impairment on PROMIS Global Mental Health

Note: Actor and partner effects of PROMIS sleep-related impairment on PROMIS global mental health summary
score. In the graphical representation above, the rectangles represent the independent and dependent variables; the
two circles on the right present the latent error terms; and the arrows describe the actor and partner effects. The
curved double-headed arrows on the left represent the covariances between the independent variables, and the
curved double-headed arrow on the right the correlation between the two error terms. The solid lines represent the
actor effects and the dashed lines represent the partner effects. Standardized coefficients and standard errors are
reported in parentheses. The model did not include control variables.
*
p < 0.05, **p < 0.001
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Table 4.8: Actor-Partner Interdependence Model parameter estimates for sleep-related
impairment and physical and mental health
Model 3: Physical health
(PROMIS GPH summary score)

Model 4: Mental health
(PROMIS GMH summary score)

Unstandardized estimate
(95% CI)

p-value

Unstandardized estimate
(95% CI)

p-value

a1

-0.323 (-0.461, -0.170)

<0.001

-0.322 (-0.485, -0.104)

0.001

a2

-0.488 (-0.616, -0.353)

<0.001

-0.346 (-0.469, -0.216)

<0.001

p12

-0.135 (-0.256, -0.013)

0.026

-0.111 (-0.263, 0.023)

0.127

p21

-0.007 (-0.144, 0.128)

0.922

-0.058 (-0.201, 0.077)

0.409

Actor effects

Partner effects

Dyadic patterns
Couple-oriented for PWP and actororiented for caregiver (k1 = 1, k2 = 0)

Actor-oriented for PWP and caregivers
(k1 = 0, k2 = 0)

k1

0.419 (0.034, 1.356)

0.345 (-0.054, 2.060)

k2

0.014 (-0.252, 0.333)

0.169 (-0204, 0.773)

2

2

4.445

3.683

0.106 (0.000, 0.243)

0.088 (0.000, 0.229)

0.977

0.973

Hypothesis

Model fit
df

Chi-square
RMSEA
(90% CI)
CFI

a1 = actor effect (PWP), a2 = actor effect (caregiver), p12 = impact of caregiver’s sleep-related impairment on PWP’s
physical/mental health (partner effect), p21 = impact of PWP’s sleep-related impairment on their caregiver’s
physical/mental health (partner effect), k1 and k2 = k (ratio) parameters to estimate dyadic patterns for PWP and
caregiver, respectively, df = degrees of freedom, RMSEA = root mean square error of approximation, CI =
confidence interval, CFI = comparative fit index
The model did not include control variables.
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Discussion
Our study aimed to assess the impact of sleep disturbance and related impairment on
global physical and mental health in PWP-caregiver dyads. For this purpose, we conducted an
online survey in a national convenience sample of PWP and caregivers. The results indicate that
both PWP and caregivers included in our study had GPH and GMH summary scores less than
50, indicating reduced physical and mental health compared to the standard US population. This
finding is consistent with previous literature.41–44 Additionally, PWP reported lower GPH and
GMH summary scores than their caregivers. Both the dyad members scored higher on PROMISSD and PROMIS-SRI than the average for the standard US population, indicating worse sleep
disturbance and related impairment in this sample.
We could not find studies which evaluated PROMIS-SD and PROMIS-SRI scores in
samples comparable to our study. However, other studies conducted by Trout et al.,45 who
analyzed an early-PD cohort, and Shin et al.,46 who analyzed an advanced PD cohort, reported
PROMIS-SD scores comparable to our results. The mean PROMIS-SD scores for PWP and
caregivers were similar, which was similar to the findings reported in Shin et al.46 The mean
PROMIS-SRI scores reported in the Trout et al.45 study in an early-PD cohort (with RBD: 31,
range: [27-49] and without RBD: 34, range: [26, 38]) are substantially lower than the score we
found in our PWP group, which may be attributed to differences in sample characteristics and the
strong correlation between disease duration and daytime sleepiness issues in PWP.47,48 PWP
reported higher scores on PROMIS-SRI than their caregivers, which was consistent with the
direction reported in Shin et al.46

132

Finally, using APIM, the current study found that sleep disturbances showed significant
negative actor effects on their own physical as well as mental health for both PWP and
caregivers. Additionally, caregiver’s sleep disturbance showed a significant negative partner
effect on PWP’s global physical health. Sleep-related impairment also significantly negatively
impacted their own physical and mental health for both PWP and caregivers. A negative partner
effect was seen between caregiver’s sleep-related impairment and their PWP’s global physical
health. To our knowledge, the current study is the first to evaluate the dyadic relationship
between sleep and HRQoL in PWP and their caregivers. Our findings provide empirical evidence
to support the negative couple-oriented effects for PWP since their physical health was
influenced by their own sleep measures as well as their caregiver’s sleep measures. We
hypothesize that sleep and wakefulness problems in caregivers might compromise their ability to
provide required care to their PWP and thereby result in worse physical health outcomes for the
PWP.
Since there was no precedent for this phenomenon in PD, we looked to literature outside
of PD and found several studies where impact of sleep was evaluated in spousal dyads. In a study
by Al-Rawashdeh et al., the authors assessed the impact of sleep disturbances on quality of life
of heart failure patients and identified a couple-oriented effect for the patient’s mental health.49
Strawbridge et al. found that older adults whose spouses experienced sleep problems were at a
greater odds of reporting fair or poor physical health.50 Another dyadic study involving middleaged and older adult couples showed that insomnia in wives increased their husband’s risk of
incident heart disease.51 While most of these studies analyzed spousal dyads, we found
significant partner effects in our sample where about 40% of caregivers were either adult
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children, other relative or other non-relative. Further research needs to be done to evaluate the
reproducibility of our results in other PD samples as well as in other disease areas.
There are some limitations in our study. First, the analysis was conducted with a
convenience sample, so the results may not be generalizable to the larger PD community. As
evident from the PWP and caregiver responses to COVID-19 related questions, the pandemic
and the consequent restrictions may have influenced respondents’ sleep and HRQoL scores and
the relationships between them. Additionally, 41% of the dyads were non-spouses, which may
have also affected the relationship between sleep and HRQoL. This was a cross-sectional study
and therefore, causality cannot be established. PWP and caregiver responses to the survey
questions may be prone to recall bias and social desirability bias.
Conclusion
Most studies usually evaluate the impact of PWP clinical factors on caregiver outcomes
such as caregiver burden or HRQoL. Our results emphasize that interventions targeted at
improving HRQoL in PWP may benefit from addressing sleep problems at the dyad-level, rather
than the individual. Our results also underscore the importance of appropriately assessing and
managing sleep problems in caregivers in a timely manner. This may help reduce distress,
improve wellbeing and decrease disease burden on the society.
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CHAPTER 5: DISSERTATION SUMMARY AND FUTURE DIRECTIONS
Summary
Parkinson’s disease (PD) is the second most common neurodegenerative disease. It is
most commonly recognized by its motor symptoms which include motor rigidity, bradykinesia,
tremors at rest, akinesia, gait and balance problems. However, evolving knowledge of the disease
has brought to fore several non-motor symptoms (NMS) such as sleep disorders, psychosis,
cognitive decline, mood disorders, orthostatic hypotension, pain etc. Several studies have shown
the impact of these NMS as debilitating to the health-related quality of life (HRQoL) of a person
with Parkinson’s disease (PWP).1 Among these NMS, sleep is particularly interesting due to its
direct influence on HRQoL2–5 and other PD symptoms such as fatigue,6 mood disturbances7 and
cognition,8 which may further compromise HRQoL among PWP. Additionally, PWP’s sleep as
well as caregiver’s sleep negatively impact caregiver HRQoL and burden.9–14 However, the
biggest limitation with these studies is that the sleep-HRQoL relationship has been considered
independent among PWP and their caregivers and there are no studies which have evaluated this
relationship from a dyadic perspective.
Therefore, this dissertation focused on three aspects: (i) a systematic review synthesizing
the literature on the impact of sleep on HRQoL in PWP and their caregivers, (ii) a cross-sectional
study evaluating psychometric properties of the Patient-Reported Outcomes Measurement
Information System (PROMIS) Global Health, a 10-item generic HRQoL instrument among
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PWP, and (iii) a cross-sectional study assessing the dyadic relationship between sleep and
HRQoL among PWP and their caregivers.
Study 1
The systematic review yielded 37 studies, of which 31 studies assessed PWP’s HRQoL
and six assessed HRQoL or burden among caregivers of PWP. Most studies included in the
review suggested that PWP’s sleep is an important predictor of their own HRQoL and their
caregiver’s HRQoL or burden. However, there was some ambiguity in terms of whether
nighttime sleep quality or daytime wakefulness played a bigger role in influencing PWP’s
HRQoL. Additionally, studies also showed that both PWP’s sleep and caregiver’s sleep are
significant predictors of caregiver HRQoL. In our review of the literature, we observed caregiver
burden as one of the outcomes which has been evaluated in some studies. However, all studies
viewed the sleep-HRQoL interactions to be independent for PWP and their caregivers.
Multivariable methods and structural equation modeling were commonly used to analyze these
data. Some studies also suggested the role of depression as a mediator in the relationship
between PWP or caregiver’s sleep on their own HRQoL. None of the studies evaluated the
impact of caregiver’s sleep on PWP outcomes.
Study 2
The cross-sectional study validating PROMIS Global Health found that the global
physical health (GPH) and global mental health (GMH) summary scores obtained from this
instrument showed good reliability in PWP. The instrument showed strong factorial validity and
no differential item functioning (DIF) between males and females. However, the scale showed
DIF by age (50-65 vs. 66+ years) on an item asking PWP to rate their fatigue. After controlling
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for the noninvariance of the fatigue item, no other items showed DIF between the two age
groups. PWP who are 66 years or older might have progressed to a more advanced stage of
Parkinson’s disease (PD) or may be experiencing additional disabilities, which could contribute
to this difference in perception regarding levels of fatigue.
In our original protocol, we had proposed to evaluate DIF by race/ethnicity as well.
However, the study sample mostly comprised of White/Caucasian individuals (201 of 261) and
each of the racial and ethnic groups had less than 20 individuals each. A multiple-groups
confirmatory factor analysis entails the simultaneous analysis of measurement models within
each group being compared. Since the sample sizes for non-White racial/ethnic groups were very
low, this process would not have been possible and therefore, exploring DIF by race/ethnicity
was dropped from the analysis plan. However, given that the PROMIS Global Health instrument
was developed and validated in a predominantly White sample,15,16 and the evolving
conversations about racial inequities,17,18 we recognize that this is an important scale property
that needs to be evaluated before this instrument can be recommended for regular use across
various segments of the population in clinical practice and in research. Further studies are
required to evaluate DIF in a more diverse racial and ethnic sample.
Additionally, GPH and GMH were able to discriminate between PWP with mild,
moderate and severe non-motor symptoms. While GPH was sensitive to different levels of motor
symptom severity, GMH was only able to discriminate mild cases from moderate and severe
groups. To our knowledge, this is the first study to evaluate the psychometric properties of the
PROMIS Global Health in PWP and the instrument demonstrated good factorial validity, knowngroups validity and internal consistency reliability.
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Study 3
This cross-sectional study assessed the dyadic relationship between sleep and HRQoL
among PWP and their caregivers using the Actor-Partner Interdependence Model (APIM).
PROMIS sleep disturbance (SD) and PROMIS sleep-related impairment (SRI) were used to
measure nocturnal and diurnal sleep issues, respectively. Results showed significant actor
effects, i.e. both SD and SRI in PWP and their caregivers were significant predictors of their
respective HRQoL. Additionally, significant partner effects were observed from caregiver to
patient, i.e. caregiver’s SD and SRI were significant predictors of PWP’s HRQoL. These
findings show that caregiver’s sleep issues had a negative impact on PWP’s HRQoL, a
relationship which is often ignored in this dynamic. This is the first study to our knowledge to
use a dyadic analytic method to evaluate the sleep-HRQoL relationship in PWP-caregiver dyads.
The study highlights the interdependent nature of this relationship between PWP and their
caregivers and provides empirical evidence to support the important role of caregiver’s sleep in
affecting PWP’s outcomes.
Study implications for clinical practice
These study findings have implications for clinical practice and policy. First, sleep
problems are common among PWP and their caregivers. Second, sleep problems in PWP and
their caregivers severely compromise their own HRQoL. Third, the study’s most important
contribution to the PD literature, caregiver’s sleep problems negatively affect their PWP’s
HRQoL. Hence, it logically follows that any interventions addressing sleep issues among
caregivers might, in turn, improve their PWP’s HRQoL. While there are several resources made
available to caregivers regarding the burdens of providing care at present, there are few
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mechanisms in place to actively identify and address their health issues. One of the ways this can
be addressed is by screening caregivers for sleep problems during the PWP’s visit to a clinician.
Another potential solution could involve healthcare professionals and researchers developing
innovative models of care where the PWP-caregiver dyad is the focus of the treatment plan
rather than the PWP alone. Addressing sleep problems in caregivers not only improves HRQoL
in PWP, but also reduces the burden on them and the healthcare system and could potentially
translate into lower healthcare resource utilization and cost of PD care.
Future directions
Our systematic review showed that sleep problems are common among PWP and their
caregivers and that both PWP and caregiver’s sleep negatively influence caregiver’s HRQoL. A
future systematic review could investigate the impact of PWP and caregiver’s sleep on caregiver
burden. Additionally, researchers could consider investigating the various non-pharmacological
and pharmacological interventions that are currently being used to address sleep issues in this
patient population and how these interventions might impact PWP outcomes. Additionally,
studies could also aim to identify various treatment modalities and services (such as hired
caregivers or respite services) available to caregivers, uptake of these services in PD and
evaluate their impact on caregiver burden and HRQoL.
The current study evaluated internal consistency reliability, factorial validity, differential
item functioning and known-groups validity of the PROMIS Global Health questionnaire in a
sample of PWP. Future studies could consider evaluating other forms of validity for the scale
such as convergent and discriminant validity with other measures commonly used in PD.
Additionally, its performance can also be evaluated in a direct comparison to legacy HRQoL
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instruments in this patient population. The scale’s responsiveness to change in HRQoL over time
can also be evaluated. A scale that is responsive to change would be useful in evaluating the
effectiveness of any innovative patient-caregiver dyad-focused interventions in improving
HRQoL. In our sample, 67% of PWP reported worsened HRQoL post-COVID-19, while 32%
reported that their HRQoL remained the same. As a future study, it would be interesting to
compare the GPH and GMH summary scores as well as the factor structures between these two
groups.
Further, this study also provided evidence to support our hypothesis that there is a dyadic
relationship between sleep and HRQoL in PWP and their caregivers. Our systematic review
suggested that depression mediates the relationship between sleep and HRQoL in PWP as well as
older adults. Studies could assess if depression also mediates the path from sleep to HRQoL
assuming dependency between PWP and their caregivers. In addition, a test of the dyadic effect
of depression and anxiety on HRQoL might also be worth investigating. Moreover, there is
evolving literature that suggests that sleep plays an important role in other neurological
conditions such as Alzheimer’s disease and hence, future studies might consider replicating the
API model suggested in our study in these conditions.
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Appendix 1: Methodological characteristics of included studies that reported burden among caregivers of persons with
Parkinson’s disease
Study design

Publication Year,
Design
Country
Carod-Artal et
al.32

Recruitment
method

Participant characteristics
Source of
participants

Sample size

Age in years
Female (%)
(Mean ± SD)

Relationship to
care recipient

CS

Consecutive

Outpatient
Neurology
clinic

50

55.7 ± 13.1

88

Spouse (78%),
Daughter/Son
(14%), Other
family
members/friends
(8%)

CS

NR

Outpatient
clinics

101

62.3 ± 10.0

63

NR

Consecutive

Movement
Disorders
Clinic

85

50.8 ± 12.7

78.8

Wife (38.8%),
Husband
(10.6%),
Sons/Daughters
(37.6%),
Cousins (5.9%),
Friends (1.2%),
Hiring
caregivers
(2.4%), Others
(3.5%)

2013
Brazil
Happe et al.28
2002
Germany
Viwattanakulvanid CS
et al.29
2014
Thailand

Range: 24-76

150

Author,
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CS = Cross-sectional, SD = Standard deviation, NR = Not reported, PS = prospective

Appendix 2: Sleep, health-related quality of life among caregivers of persons with Parkinson’s disease

Publication Year,

HRQoL and caregiver
burden measurement tool
and score

Mean ± SD

Mean ± SD

Country
Patients
Carod-Artal et
al.32
2013
Brazil

SCOPAsleep: 10.1
± 6.1

Caregivers
NR

Range: 0-14

Patients

HRQoL and caregiver
burden results

Study limitations

Caregivers

EQ-5D
index:

ZCBI: 20.2 ±
12.8

0.5 ± 0.3

Range: 1-61

Range: 0.24 to 1

Patient sleep was associated
with increased caregiver
burden but was not
significantly associated with
caregiver’s HRQoL.

− Small sample
size (N = 50)
− Increased type
I error due to
number of
analyses
performed

Caregiver burden was a
significant predictor of bad
sleep.

− Only baseline
assessments
were available
whereas the
original study
was
longitudinal

EQ-5D
VAS:
63.6 ± 19.8
Range: 0100
Happe et al.28
2002
Germany

Questions
about sleeprelated
problems

Questions
NR
about sleeprelated
problems

34% of the
patients

27% of the
caregivers

CBI: scores
were not
reported
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Author,

Sleep measurement tool
& score

Viwattanakulvanid MPDSS:
et al.29
146.9 ±
24.6
2014
Range: 91Thailand
184

reported
bad nighttime sleep
NR

PDQ-8:
22.7 ± 15.7

ZCBI: 15.9 ±
12.6

Range: 068.75

Range: 1-50

Patient’s sleep (MPDSS)
− Recall bias
and stressful
was a significant predictor of
situation may
caregiver burden.
result in less
accurate
answers

SD = standard deviation, HRQoL = Health-related quality of life, PDSS = Parkinson’s disease sleep scale, ESS = Epworth Sleepiness Scale, MOS-SS = Medical
Outcomes Study – Sleep Scale, PDQ = Parkinson’s Disease Questionnaire, SF-36 = Short Form-36, PHS = Physical health scale, MHS = Mental health scale,
CBI = Caregiver Burden Inventory, SCOPA = Scales for Outcomes in Parkinson’s disease, NR = not reported, EQ-5D = EuroQol-5 Dimension, ZCBI = Zarit
Caregiver Burden Inventory, PSQI = Pittsburgh Sleep Quality Index, MQoL = McGill Quality of Life Questionnaire, WHOQOL-BREF = World Health
Organization Quality of Life Assessment-Bref, SDI = Sleep Disturbances Inventory, MPDSS = Modified Parkinson’s Disease Sleep Scale
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reported
bad nighttime sleep

Appendix 3: Quality appraisal of included caregiver studies
Author
Carod-Artal et
al.32
Happe et al.28
Viwattanakulvanid
et al.29

Year

Q1

Q2

Q3

Q4

Q5

Q6

Q7

Q8

Q9

2013

Y

Y

Y

Y

Y

Y

Y

Y

Include

2002

Y

Y

Y

Y

Y

Y

Y

Y

Include

2014

Y

Y

Y

Y

Y

Y

Y

Y

Include

Q10
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Y = Yes
*
Q1-Q10 correspond to items in the quality appraisal form presented in Table 2.2.

Appendix 4: Survey instrument for persons with Parkinson's disease
GENERAL INSTRUCTIONS: For each of the following questions please check the most
appropriate response.

Are you a person living with Pakinson's disease?

o Yes (1)
o No (2)
Are you at least 50 years old?

o Yes (1)
o No (2)
Have you participated in a survey regarding sleep and quality of life with the University of
Mississippi in the past one year?

o Yes (1)
o No (2)
End of Block: Screener
Start of Block: General instructions
INSTRUCTIONS
This survey has five sections, which contain questions about your health, sleep and quality of life
as well as the impact of COVID-19 pandemic. Please note that there are no right or wrong
answers to any of the following questions.

End of Block: General instructions
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Start of Block: Section I: Health-related quality of life
PROMIS® Scale v1.2 – Global Health
2010-2018 PROMIS Health Organization (PHO)
INSTRUCTIONS
This survey asks about your health and quality of life. There are no right or wrong answers. For
each item, please select the response that best describes your answer.
Please respond to each question or statement by marking one box per row.
Excellent
(1)

Very good
(2)

Good (3)

Fair (4)

Poor (5)

In general, would you
say your health is: (1)

o

o

o

o

o

In general, would you
say your quality of life
is: (2)

o

o

o

o

o

In general, how would
you rate your physical
health? (3)

o

o

o

o

o

In general, how would
you rate your mental
health, including your
mood and your ability to
think? (4)

o

o

o

o

o

In general, how would
you rate your satisfaction
with social activities and
relationships? (5)

o

o

o

o

o

In general, please rate
how well you carry out
your usual social
activities and roles. (This
includes activities at
home, at work and in
your community, and
responsibilities as a
parent, child, spouse,
employee, friend, etc.)
(6)

o

o

o

o

o
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Completely
(1)
To what extent are
you able to carry out
your everyday
physical activities
such as walking,
climbing stairs,
carrying groceries, or
moving a chair? (1)

o

Never
(1)
In the past 7 days, how
often have you been
bothered by emotional
problems such as
feeling anxious,
depressed or irritable?
(1)

o

None
(1)
In the past 7 days, how
would you rate your
fatigue on average? (1)

Mostly (2)

o

Moderately
(3)

o

Rarely (2)

o

o

Sometimes
(3)

o

Mild (2)

o

Moderate (3)

o
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A little (4)

o

Often (4)

o

Severe (4)

o

Not at all
(5)

o

Always (5)

o

Very severe
(5)

o

In the past 7 days, how would you rate your pain on average?

o 0 (0)
o 1 (1)
o 2 (2)
o 3 (3)
o 4 (4)
o 5 (5)
o 6 (6)
o 7 (7)
o 8 (8)
o 9 (9)
o 10 (10)
End of Block: Section I: Health-related quality of life
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Start of Block: Section II: Sleep disturbances

PROMIS® Item Bank v1.0 – Sleep Disturbance – Short Form 8a
2008-2020 PROMIS Health Organization (PHO)
INSTRUCTIONS
This survey asks about your nighttime sleep-related disturbances. There are no right or wrong
answers. For each item, please select the response that best describes your answer. Please
respond to each question or statement by marking one box per row.

Very
poor
(1)
In the past 7 days, my
sleep quality was
........................ (1)

o

Poor (2)

o
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Fair (3)

o

Good (4)

o

Very good
(5)

o

In the past 7 days...
Not
at all
(1)
My sleep was
refreshing (1)

A little bit
(2)

Somewhat
(3)

Quite a bit
(4)

Very much
(5)

I tried hard to get to
sleep (5)

o
o
o
o
o

o
o
o
o
o

o
o
o
o
o

o
o
o
o
o

o
o
o
o
o

I worried about not
being able to fall asleep
(6)

o

o

o

o

o

I was satisfied with my
sleep (7)

o

o

o

o

o

I had a problem with
my sleep (2)
I had difficulty falling
asleep (3)
My sleep was restless
(4)

End of Block: Section II: Sleep disturbances
Start of Block: Section III: Sleep-related impairment

PROMIS Item Bank v. 1.0 – Sleep-Related Impairment – Short Form 8a
2008-2016 PROMIS Health Organization and PROMIS Cooperative Group
INSTRUCTIONS
This survey asks about your sleep-related functioning during waking hours. There are no right or
wrong answers. For each item, please select the response that best describes your answer. Please
respond to each question or statement by marking one box per row.
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In the past 7 days...
Not
at all
(1)
I had a hard time
getting things done
because I was sleepy
(1)

A little bit
(2)

Somewhat
(3)

Quite a bit
(4)

Very much
(5)

o

o

o

o

o

o
o

o
o

o
o

o
o

o
o

I had problems
during the day
because of poor sleep
(4)

o

o

o

o

o

I had a hard time
concentrating
because of poor sleep
(5)

o

o

o

o

o

I felt irritable
because of poor sleep
(6)

o

o

o

o

o

I was sleepy during
the daytime (7)

o

o

o

o

o

I had trouble staying
awake during the day
(8)

o

o

o

o

o

I felt alert when I
woke up (2)
I felt tired (3)

End of Block: Section III: Sleep-related impairment
Start of Block: Section IV: Information about you and your health

Q18
INSTRUCTIONS

161

Please answer the following questions on general information about you and your health. Please
select the option that best describes your answer.

What is your sex?

o Female (1)
o Male (2)
o Other/prefer not to answer (3)
What is your age (in years)?

o 50-65 (1)
o 66-75 (2)
o 76-85 (3)
o 86 or older (4)
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Which of the following best describes your race or ethnicity? Check ALL that apply.

▢
▢
▢
▢
▢
▢
▢

American Indian/Alaskan Native (1)
Asian (2)
Black/African American (3)
Hispanic or Latino (4)
Native Hawaiian/Other Pacific Islander (5)
White/Caucasian (6)
Other (please specify) (7) _____________________________

What is the highest level of education you have completed?

o No degree (1)
o GED or High school diploma (2)
o Associate's degree (3)
o Bachelor's degree (4)
o Master's degree (5)
o Terminal degree (e.g., JD, MD, PhD) (6)
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What is your current primary employment status?

o Employed for wages (1)
o Self-employed (2)
o Out of work for 1 year or more (3)
o Out of work for less than 1 year due to COVID-19, also known as Coronavirus or SARSCoV-2 (4)

o Out of work for less than 1 year due to other reason(s) (5)
o A homemaker (6)
o A student (7)
o Retired (8)
o Unable to work (9)
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What type of health insurance do you currently have?

o Public insurance (e.g., Medicare, Medicaid, VA) (1)
o Private insurance (2)
o Other (please specify) (3) ___________________________
Please choose the response below that best describes the severity of your motor symptoms over
the past week.

o Normal (1)
o Borderline (2)
o Mild (3)
o Moderate (4)
o Severe (5)
o Extreme (6)

165

Please choose the response below that best describes the severity of your non-motor symptoms
over the past week.

o Normal (1)
o Borderline (2)
o Mild (3)
o Moderate (4)
o Severe (5)
o Extreme (6)
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The following list includes drugs that can help you with your Parkinson's symptoms or sleep or
both. Please indicate which of the following you are currently taking. Check ALL that apply.

▢
▢
▢
▢
▢
▢
▢
▢
▢
▢
▢
▢
▢
▢
▢
▢

Sinemet CR (carbidopa and levodopa) Sustained-Release Tablets (1)
Rytary (carbidopa and levodopa) Extended-Release Capsules (10)
Neupro (Rotigotine Transdermal System) (7)
Requip (ropinirole) (23)
Mirapex (pramipexole) (24)
Silenor (doxepin) (14)
Ambien (zolpidem) (11)
Sonata (zaleplon) (12)
Provigil (modafinil) (16)
Nuvigil (armodafinil) (17)
Ritalin (methylphenidate) (22)
Lunesta (eszopiclone) (2)
Klonopin (clonazepam) (18)
Deep brain stimulation (5)
Nuplazid (pimavanserin) (19)
Duopa (Carbidopa and Levodopa) Enteral Suspension (3)
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▢
▢
▢
▢
▢

Desyrel (trazodone) (15)
Seroquel (quetiapine) (21)
Clozaril (clozapine) (20)
Melatonin supplements (13)
Other (please specify) (6) __________________________________________

Have you ever had or currently have any of the following health conditions? (Check ALL that
apply)

▢
▢
▢
▢
▢
▢
▢
▢
▢

None (1)
Alzheimer's disease and other dementias (2)
Arthritis (rheumatoid arthritis, osteoarthritis, gout etc.) (3)
Asthma (4)
Bone marrow or other organ transplant (5)
Cancer (6)
Chronic kidney disease (7)
Chronic lung disease (COPD, emphysema, chronic bronchitis) (8)
Diabetes (9)
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▢
▢
▢
▢
▢
▢

Heart disease (high blood pressure, heart failure etc.) and stroke (10)
HIV/AIDS (11)
Liver disease (12)
Mood disorders (depression, anxiety etc.) (13)
Obesity (14)
Other chronic conditions (please specify) (15) ____________________________

End of Block: Section IV: Information about you and your health
Start of Block: Section V: Impact of COVID-19
INSTRUCTIONS
Please answer the following questions to help us understand the impact of COVID-19 pandemic,
also known as Coronavirus or SARS-CoV-2, on your sleep and quality of life.
Have you heard about the infectious disease called COVID-19, also known as Coronavirus or
SARS-Cov-2?

o Yes (1)
o No (2)
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How would you rate your anxiety about the COVID-19 pandemic?

o 1 (Low anxiety) (1)
o 2 (2)
o 3 (3)
o 4 (4)
o 5 (5)
o 6 (6)
o 7 (7)
o 8 (8)
o 9 (9)
o 10 (High anxiety) (10)
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Please answer the following questions about the impact of the COVID-19 pandemic on your
sleep and quality of life.
Strongly
disagree
(1)

Somewhat
disagree (2)

Neither
agree nor
disagree (3)

Somewhat
agree (4)

Strongly
agree (5)

The COVID-19
pandemic has had a
significant impact on
the quality of my sleep
(1)

o

o

o

o

o

The COVID-19
pandemic has had a
significant impact on
my quality of life (2)

o

o

o

o

o

Please complete the following sentence: As a result of the COVID-19 pandemic, the quality of
my sleep has ......................

o Worsened (1)
o Remained the same (2)
o Improved (3)
Please complete the following sentence: As a result of the COVID-19 pandemic, my quality of
life has ......................

o Worsened (1)
o Remained the same (2)
o Improved (3)
End of Block: Section V: Impact of COVID-19
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Appendix 5: Survey instrument for caregivers of persons with Parkinson’s disease
Start of Block: Screener
GENERAL INSTRUCTIONS: For each of the following questions please check the most
appropriate response.

Are you the primary informal caregiver of a family member or friend who has Parkinson’s
disease? An informal caregiver is someone who provides care to a care recipient with whom
he/she has a personal relationship with (such as a family member, a friend etc.).

o Yes (1)
o No (2)
Is your primary care recipient with Parkinson's disease at least 50 years old?

o Yes (1)
o No (2)
Do you live in the same household as your primary care recipient with Parkinson's disease?

o Yes (1)
o No (2)
Have you or your primary care recipient with Parkinson's disease participated in a survey
regarding sleep and quality of life with the University of Mississippi in the past one year?

o Yes (1)
o No (2)
End of Block: Screener
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Start of Block: General instructions
INSTRUCTIONS
This survey has five sections, which contain questions about your sleep and quality of life as
well as your caregiving activities. Please note that there are no right or wrong answers to any of
the following questions.

End of Block: General instructions
Start of Block: Section I: Health-related quality of life
PROMIS® Scale v1.2 – Global Health
2010-2018 PROMIS Health Organization (PHO)
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INSTRUCTIONS This survey asks about your health and quality of life. There are no right or
wrong answers. For each item, please select the response that best describes your answer.
Please respond to each question or statement by marking one box per row.
Excellent
(1)
In general, would you say
your health is: (1)

Very good
(2)

Good (3)

Fair (4)

Poor (5)

In general, would you say
your quality of life is: (2)

o
o

o
o

o
o

o
o

o
o

In general, how would
you rate your physical
health? (3)

o

o

o

o

o

In general, how would
you rate your mental
health, including your
mood and your ability to
think? (4)

o

o

o

o

o

In general, how would
you rate your satisfaction
with social activities and
relationships? (5)

o

o

o

o

o

In general, please rate
how well you carry out
your usual social
activities and roles. (This
includes activities at
home, at work and in
your community, and
responsibilities as a
parent, child, spouse,
employee, friend, etc.)
(6)

o

o

o

o

o
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Completely
(1)
To what extent
are you able to
carry out your
everyday
physical
activities such
as walking,
climbing stairs,
carrying
groceries, or
moving a chair?
(1)

o

o

Never
(1)
In the past 7 days,
how often have you
been bothered by
emotional problems
such as feeling
anxious, depressed or
irritable? (1)

o

None
(1)
In the past 7 days,
how would you rate
your fatigue on
average? (1)

Moderately
(3)

Mostly (2)

o

Rarely (2)

o

Mild (2)

o

o

Sometimes
(3)

Often (4)

o

Moderate (3)

o

o
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A little (4)

o

Severe (4)

o

Not at all (5)

o

Always (5)

o

Very severe
(5)

o

In the past 7 days, how would you rate your pain on average?

o 0 (0)
o 1 (1)
o 2 (2)
o 3 (3)
o 4 (4)
o 5 (5)
o 6 (6)
o 7 (7)
o 8 (8)
o 9 (9)
o 10 (10)
End of Block: Section I: Health-related quality of life
Start of Block: Section II: Sleep disturbances
PROMIS® Item Bank v1.0 – Sleep Disturbance – Short Form 8a
2008-2020 PROMIS Health Organization (PHO)
INSTRUCTIONS
This survey asks about your nighttime sleep-related disturbances. There are no right or wrong
answers. For each item, please select the response that best describes your answer. Please
respond to each question or statement by marking one box per row.
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Very
poor
(1)
In the past 7 days, my
sleep quality was
........................ (1)

o

Poor (2)

Fair (3)

o

o

Good (4)

o

Very good
(5)

o

In the past 7 days...
Not at
all (1)
My sleep was
refreshing (1)

A little bit
(2)

Somewhat
(3)

Quite a bit
(4)

Very much
(5)

I tried hard to get to
sleep (5)

o
o
o
o
o

o
o
o
o
o

o
o
o
o
o

o
o
o
o
o

o
o
o
o
o

I worried about not
being able to fall
asleep (6)

o

o

o

o

o

I was satisfied with my
sleep (7)

o

o

o

o

o

I had a problem with
my sleep (2)
I had difficulty falling
asleep (3)
My sleep was restless
(4)

End of Block: Section II: Sleep disturbances

Start of Block: Section III: Sleep-related impairment
PROMIS Item Bank v. 1.0 – Sleep-Related Impairment – Short Form 8a
2008-2016 PROMIS Health Organization and PROMIS Cooperative Group
INSTRUCTIONS
This survey asks about your sleep-related functioning during waking hours. There are no right or

177

wrong answers. For each item, please select the response that best describes your answer. Please
respond to each question or statement by marking one box per row.
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In the past 7 days...
Not at
all (1)
I had a hard time
getting things done
because I was
sleepy (1)

A little bit
(2)

Somewhat
(3)

Quite a bit
(4)

Very much
(5)

o

o

o

o

o

o
o

o
o

o
o

o
o

o
o

I had problems
during the day
because of poor
sleep (4)

o

o

o

o

o

I had a hard time
concentrating
because of poor
sleep (5)

o

o

o

o

o

I felt irritable
because of poor
sleep (6)

o

o

o

o

o

I was sleepy during
the daytime (7)

o

o

o

o

o

I had trouble
staying awake
during the day (8)

o

o

o

o

o

I felt alert when I
woke up (2)
I felt tired (3)

End of Block: Section III: Sleep-related impairment
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Start of Block: Section IV: Information about you, your health and caregiving
responsibilities
INSTRUCTIONS
Please answer the following questions to help us better understand your role as a caregiver.
Please select the option that best describes your answer.

What is your sex?

o Female (1)
o Male (2)
o Other/prefer not to answer (3)

What is your current age (in years)?
________________________________________________________________
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Which of the following best describes your race or ethnicity?

▢
▢
▢
▢
▢
▢
▢

American Indian/Alaskan Native (1)
Asian (2)
Black/African American (3)
Hispanic or Latino (4)
Native Hawaiian/Other Pacific Islander (5)
White/Caucasian (6)

Other (please specify) (7)
________________________________________________
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What is the highest level of education you have completed?

o No degree (1)
o GED or High school diploma (2)
o Associate's degree (3)
o Bachelor's degree (4)
o Master's degree (5)
o Terminal degree (e.g., JD, MD, PhD) (6)
Are you currently ....?

o Employed for wages (1)
o Self-employed (2)
o Out of work for 1 year or more (3)
o Out of work for less than 1 year due to COVID-19, also known as Coronavirus or SARSCoV-2 (4)

o Out of work for less than 1 year due to other reason(s) (5)
o A homemaker (6)
o A student (7)
o Retired (8)
o Unable to work (9)
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What is your annual household income from all sources?

o Less than $15,000 (1)
o $15,000 to less than $25,000 (2)
o $25,000 to less than $35,000 (3)
o $35,000 to less than $50,000 (4)
o $50,000 or more (5)
What type of health insurance do you currently have?

o Public insurance (e.g., Medicare, Medicaid, VA) (1)
o Private insurance (2)
o Other (please specify) (3) ________________________________________________
For how many children and adults are you the primary informal caregiver (including your
primary care recipient with Parkinson's disease)?
________________________________________________________________
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Have you ever had or currently have any of the following health conditions? (Check ALL that
apply)

▢
▢
▢
▢
▢
▢
▢
▢
▢
▢
▢
▢
▢
▢
▢

None (1)
Alzheimer's disease and other dementias (2)
Arthritis (rheumatoid arthritis, osteoarthritis, gout etc.) (3)
Asthma (4)
Bone marrow or other organ transplant (5)
Cancer (6)
Chronic kidney disease (7)
Chronic lung disease (COPD, emphysema, chronic bronchitis) (8)
Diabetes (9)
Heart disease (high blood pressure, heart failure etc.) and stroke (10)
HIV/AIDS (11)
Liver disease (12)
Mood disorders (depression, anxiety etc.) (13)
Obesity (14)

Other chronic conditions (please specify) (15)
________________________________________________
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Has a doctor, nurse, or other health professional ever told you that you have a sleep disorder?

o Yes (1)
o No (2)
o Uncertain (3)
Are you currently taking any medications or supplements (such as melatonin) to help with your
sleep?

o Yes (12)
o No (13)
o Uncertain (15)
INSTRUCTIONS
Please answer the following questions keeping in mind your primary care recipient with
Parkinson's disease.
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Which of the following best describes your relationship to your primary care recipient with
Parkinson's disease?

o Spouse or significant other (1)
o Daughter (2)
o Son (3)
o Other relative (4)
o Other non-relative (5)

What is the age of your primary care recipient with Parkinson's disease (in years)?

o 50-65 (1)
o 66-75 (2)
o 76-85 (3)
o 86 or older (4)

How many hours of caregiving do you provide per week to your primary care recipient with
Parkinson's disease?

o 20 hours or fewer (1)
o 21-39 hours (2)
o 40 hours or more (3)
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End of Block: Section IV: Information about you, your health and caregiving
responsibilities
Start of Block: Section V: Impact of COVID-19
INSTRUCTIONS
Please answer the following questions to help us understand the impact of COVID-19,
also known as Coronavirus or SARS-CoV-2, on your caregiving responsibilities.

Have you heard about the infectious disease called COVID-19, also known as Coronavirus or
SARS-Cov-2?

o Yes (1)
o No (2)
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How would you rate your anxiety about the COVID-19 outbreak?

o 1 (Low anxiety) (1)
o 2 (2)
o 3 (3)
o 4 (4)
o 5 (5)
o 6 (6)
o 7 (7)
o 8 (8)
o 9 (9)
o 10 (High anxiety) (10)
Please answer the following questions about the impact of the COVID-19 pandemic on your
sleep and quality of life.
Strongly
disagree
(1)

Somewhat
disagree (2)

Neither
agree nor
disagree (3)

Somewhat
agree (4)

Strongly
agree (5)

The COVID-19
pandemic has had a
significant impact on
the quality of my sleep
(1)

o

o

o

o

o

The COVID-19
pandemic has had a
significant impact on
my quality of life (2)

o

o

o

o

o
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Please complete the following sentence: As a result of the COVID-19 outbreak, the quality of
sleep has ......................

o Worsened (1)
o Remained the same (2)
o Improved (3)

Please complete the following sentence: As a result of the COVID-19 outbreak, my quality of
life has ......................

o Worsened (1)
o Remained the same (2)
o Improved (3)
End of Block: Section V: Impact of COVID-19

189

VITA
SUSHMITHA INGUVA, M.S., Ph.D.
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government payer
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value dossiers, Qualitative research methods
EDUCATION

University of Mississippi
University, MS
PhD candidate in Pharmaceutical Sciences
May 2021
Concentration: Pharmacy Administration; Track: Health Outcomes Research
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Research Analyst, Mississippi Medicaid Drug Utilization Review team
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disorders, Oncology
•
•
•
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Executing studies and communicating findings to internal and external stakeholders
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access and reimbursement decisions
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•
•
•

Lead analyst on Right! from the Start, a community-focused intervention to improve breastfeeding
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•
•
•
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Contributed to the planning and execution of HEOR strategy for advanced Parkinson’s disease (APD)
Developed a protocol to assess economic burden among APD patients using Medicare and Truven
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192

•

•

•

•

•

•

•

Inguva S, Allen DD, Ramachandran S, Pittman E, Banahan BF III, Noble S. Opioid Overdose risk
factors: A matched case control study in Mississippi Medicaid. International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) Annual International Meeting. Baltimore,
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